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1. Introduction
1.1 Background
Dental implants and implant-supported restorations are a predictable alternative to
removable partial dentures and fixed tooth-supported prostheses. Dental implants are
commonly used to replace missing teeth, with 4.5 million implants placed annually
worldwide. The success rate of implant therapy is greater than 90% after the first year in
function [1].

Bacterial biofilms colonize dental implants upon exposure to the oral cavity [2].
Undisrupted biofilms cause inflammation of the implant-mucosa unit, a process known as
peri-implant mucositis. Peri-implant mucositis is defined as a reversible inflammatory
condition of the mucosa without accompanying bone loss [3]. Evidence from animal
studies suggests that persistent peri-implant mucositis may progress to peri-implantitis
[4,5], which involves progressive bone loss. Loss of the affected implant may occur in
patients with peri-implantitis. According to a recent review, 80% of patients and 50% of
implants are affected with peri-implant mucositis whereas 28% of patients and 12% of
implants are affected with peri-implantitis [6]. A more comprehensive understanding of
peri-implant mucositis and the development of preventive strategies are needed.

The biology of peri-implant mucositis is not well understood. Several human and animal
studies have demonstrated that bacterial plaque accumulation produces similar clinical
responses, such as erythema, bleeding on probing and increased gingival crevicular fluid
(GCF) flow, in the tissues surrounding teeth and implants [7-9]. However, differences in
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the quality and quantity of the inflammatory infiltrate [8] and the quality of the microbial
flora [10] between gingiva and peri-implant mucosa have been reported. For example, a
study by Nowzari et al. [11] found that cytokines associated with the innate immune
response (e.g., IL-8, TNF-alpha) are exaggerated in the peri-implant mucosa in
comparison to the gingiva [11]. Thus several neutrophil (PMN) activation markers,
including myeloperoxidase and lactoferrin, have been proposed as potential risk markers
for peri-implant disease [12]. In addition, although the microbiota of peri-implant and
periodontal infections is for the most part similar [13], implant sites have been shown to
harbor organisms not traditionally associated with periodontitis, such as staphylococci
and enterics [14,15]. To date, the temporal microbial succession and resultant host
response in the peri-implant mucosa versus the periodontium, in response to plaque
accumulation, has not been characterized.

1.2 Gingivitis
1.2.1 Microbiota changes in gingivitis
Gingivitis is defined by the presence of gingival inflammation without the loss of
connective tissue attachment [16]. The etiology of gingivitis is bacterial plaque. A human
experimental gingivitis model showed a significant shift in the bacterial biofilm
composition from health to disease [17]. In this model, the microflora of healthy gingival
sites was comprised of mainly aerobic Gram-positive cocci and rods. Two to four days
after oral hygiene withdrawal, fusobacteria and filamentous bacteria proliferate. After
four to nine days, the bacterial flora was characterized by the presence of curved rods and
spirochetes. Gingivitis appeared 10 to 21 days following oral hygiene withdrawal and
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was reversible with reinstitution of oral care procedures at both the clinical and
microbiological levels. The range in the timing of the development of clinical gingivitis
among subjects was thought to be the result of variability in the individual host response
to bacterial plaque [17,18]. No study, however, has ultimately resolved the genetic,
microbiological or immunological parameters underlying susceptibility to gingival
inflammation.

Analyses of the subgingival microbiota in periodontal health and established gingivitis
have shown differences in species predominance. Actinomyces naeslundii,
Campylobacter gracilis, Prevotella nigrescens and Tannerella forsythia are increased in
gingivitis samples. Health-associated species include Streptococcus oralis, Streptococcus
gordonii, A. naeslundii and Actinomyces gerencseriae [19,20]. A three-year prospective
study demonstrated elevated counts of A. naeslundii, Capnocytophagia gingivalis and
Prevotella intermedia during baseline gingivitis and significant reductions in these
species after one, two and three years of participation in a periodontal prevention regimen
[21].

The above-cited studies have used techniques to characterize the microflora such as
cultivation and microscopic observation [18] or DNA-DNA hybridization [21]. A more
recent study used high-throughput 16S rRNA pyrosequencing to investigate the changes
in the microbiome development during experimental gingivitis, comprehensively
characterizing the bacterial communities in plaque during the health to gingivitis
transition [22]. Analyses were carried out at baseline and after one and two weeks of
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interrupted plaque control. Pyrosequencing yielded 344,267 sequences that were
clustered into an average of 299 species-level Operational Taxonomic Units (OTUs) per
sample. There was no significant difference in richness between baseline and the end of
experimental gingivitis induction (week 2). There was a significant difference in diversity
across time points, with diversity significantly higher in two-week communities
compared to both baseline and one-week communities. The significant increase in
community diversity after two weeks of experimental gingivitis in the absence of
increased richness indicates that increased diversity was due to increasing evenness.
Therefore, the dominant species in health decreased in relative abundance over time
while previously minor constituent species increased in relative abundance, resulting in a
more even distribution of species after two weeks of plaque accumulation. Comparison of
bacterial community structure of plaque samples using Principal Coordinate Analysis
(PCoA) showed spatial separation of one- and two-week communities from baseline
communities. The relative abundance of Actinobacteria was significantly higher at
baseline compared to one and two weeks while Bacteroidetes were significantly higher in
one- and two-week samples compared to baseline. However, there was considerable
variability among subjects regarding the shifts in phyla during experimental gingivitis. In
addition, the OTUs identified as Lautropia sp. HOTA94, Lachnospiraceae sp. HOT100,
Prevotella oulorum and Fusobacterium nucleatum subsp. polymorphum were most
significantly positively correlated with bleeding on probing (BOP). An OTU identified as
Rothia dentocariosa was most significantly negatively correlated with BOP. The results
of this study demonstrate that in the absence of oral hygiene, the transition from
periodontal health to gingivitis is accompanied by a shift in the bacterial community
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structure of plaque and an increase in bacterial diversity. The OTUs that increased in
relative abundance as gingivitis developed were often obligate anaerobes and mostly
gram-negative taxa of the genera Campylobacter, Fusobacterium, Lautropia,
Leptotrichia, Porphyromonas, Selenomonas and Tannerella. These findings are in
accordance with the observations of Loe and coworkers (1966), who reported an increase
in the proportion of gram-negative cocci and rods as well as filaments, spirilla and
spirochetes as gingivitis developed [18]. In the classic experimental gingivitis model,
however, subjects abstained from oral hygiene for 21 days and gingivitis did not appear
for 21 days in some subjects. The pyrosequencing study described above involved
cessation of oral hygiene practices for only 14 days. This may have resulted in the
inclusion of healthy sites among gingivitis data, when analyzing data according to time
points, which is a significant limitation. There was also great variability at the phylumand species-level among the subjects at baseline as indicated by the PCoA plots, which
may compromise the ability to observe statistically significant changes in community
structure from baseline to the gingivitis time points with a limited sample size.

A study by Huang et al. (2014) examined the structure of the plaque microbiota in an
experimental gingivitis model using pyrosequencing of the 16S rRNA gene in 50 subjects
and developed a model to predict gingivitis severity and susceptibility based on plaque
microbial structure. Five genera (e.g., Streptococcus) had elevated abundance at baseline
whereas different 22 genera (e.g., Leptotrichia) had elevated abundance in both native
and experimental gingivitis. All 150 species associated with health and gingivitis were
clustered via PCoA based on relative abundance. The healthy and diseased taxa were
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distinguished by a boundary separating baseline (healthy) samples from both native and
experimental gingivitis, suggesting that microbiota structure is related to health or disease
states. Native and experimental gingivitis microbial communities were largely consistent
with respect to this boundary in the same subject. Therefore, community changes
associated with gingivitis seem to recur similarly within subjects and each individual may
have a personalized disease-associated configuration of the microbiota [23].

Huang et al. (2014) also observed that the projected coordinate of a given microbiota on
the first principal component (PC1) of their PCoA plots demonstrated a gradient-like
development of microbiota structure during experimental gingivitis and resolution, as
changes in PC1 were consistent with the structural segregation between healthy and
diseased microbiota. Thus, PC1 was used as a proxy for quantitatively measuring the
development of the microbiota during the transition from native gingivitis to health and
health to experimental gingivitis. The authors discovered that 15 genera were the drivers
of heterogeneity among the microbiota along PC1. In health, genera traditionally
associated with periodontitis (e.g., Fusobacterium, Tannerella, Treponema) were present
in low abundance whereas their abundance increased along the PC1 axis. On the other
hand, genera associated with health (e.g., Rothia, Haemophilus) were present in low
abundance in the gingivitis samples and higher abundance in the healthy samples [23].
Additionally, gingivitis severity was correlated with PC1 values throughout the
experimental gingivitis and resolution phases. Two distinct types of hosts emerged, with
type I patients exhibiting less gingivitis sensitivity than type II patients. Type II patients
demonstrated dramatic changes in PC1/microbial structure and gingivitis severity
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compared to type I patients, who did not demonstrate such acute changes. For the average
type II host, the rates of change in PC1 and gingivitis severity were 2.21-fold and 1.89fold higher than in an average type I host. Genera including Abiotrophia, Selenomonas
and uncultured Lachnospiraceae were enriched in type II hosts compared with type I
hosts. Interestingly, compared with type I hosts, those genera associated with type II
hosts during native and experimental gingivitis were also higher in relative abundance in
type II hosts at baseline. The authors concluded that heterogeneity of plaque microbiota
among hosts may explain phenotypic variations of gingivitis sensitivity [23].

Lastly, to determine whether PC1 could model disease progression and classify patients
based on disease state, 41 additional subjects were sampled during native gingivitis and
baseline for model validation. A microbial index of gingivitis (MiG) was derived based
on the relative abundance of the 27 bacterial markers that distinguished health from
native and experimental gingivitis. The predictive power of MiG27 was tested by
determining the gingivitis statuses of the hosts using their native gingivitis microbiota.
The accuracy of classification for a diseased versus healthy state was 94%. Therefore,
plaque microbial structure is able to classify gingivitis susceptibility and severity in
humans and the plaque microbial population during native gingivitis can predict the
population structure during a later episode of experimentally-induced gingivitis in the
same subject [23].
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In summary, gingivitis is associated with a shift in the microbiome consisting of
increased gram-negative anaerobes as well as increased diversity. Plaque microbial
structure may predict susceptibility to gingivitis.

1.2.2 Host response in gingivitis
The host immune system responds dramatically to the increased bacterial burden and the
shift in community structure as plaque accumulates. The inflammatory process in patients
with gingivitis is characterized by a cellular infiltrate composed of PMNs, B- and Tlymphocytes, plasma cells, monocytes and macrophages [24,25].

The histopathology of gingivitis is characterized by four stages. The evidence for these
stages described by Page and Schroeder [26] was based on prevailing information from
animal biopsies and some human adolescent samples. The initial lesion forms within 2 to
4 days of plaque accumulation and involves vasculitis, increased GCF flow and migration
of PMNs into the junctional epithelium. Loss of both epithelial cells in the coronal aspect
of the junctional epithelium and perivascular collagen occurs. After 4 to 7 days, the early
lesion forms. This stage in the evolution of gingivitis includes an accumulation of
lymphocytes adjacent to the junctional epithelium and further loss of collagen. PMNs and
lymphocytes are the predominant leukocytes in the infiltrate at this stage of gingivitis.
The established lesion is the third stage of gingival inflammation. The distinguishing
feature of this lesion is the predominance of plasma cells. Apical migration of the
junctional epithelium and loss of connective tissue matrix elements are present.
According to Page and Schroeder, the established lesion occurs after 7 days of plaque
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accumulation. However, gingival biopsies from Brecx et al. [27] demonstrate that the
lesion throughout 21-day abstention from oral hygiene during experimental gingivitis
represents that of an early lesion, with numerous PMNs and lymphocytes but low
numbers of plasma cells. Therefore, it may take longer than three weeks for the
established lesion to develop. The established lesion may remain stable for a long period
of time or progress to the advanced lesion, which is irreversible, involving pocket
formation and bone loss [26].

The interleukin 1 (IL-1) family of cytokines, interleukin 6 (IL-6), tumor necrosis factor
alpha (TNF-alpha) and PGE2 are the cytokines and inflammatory mediators most
consistently associated with gingivitis and periodontitis [28]. IL-1 alpha and beta are proinflammatory cytokines that stimulate PGE2 release from monocytes and fibroblasts.
PGE2 then induces osteoclastic bone resorption and matrix metalloproteinase (MMP)
secretion. IL-1 beta also enables ingress of inflammatory cells into sites of infection,
promotes bone resorption and stimulates release of MMPs that degrade proteins of the
extracellular matrix. IL-1 beta is a principal mediator of the gingival inflammatory
response and is produced primarily by macrophages and PMNs. IL-6 stimulates plasma
cell proliferation and thus antibody production. IL-6 is produced by lymphocytes,
monocytes and fibroblasts. TNF-alpha shares many properties with IL-1. It is proinflammatory and stimulates MMP action, PGE2 production and bone resorption. It is
secreted by monocytes and fibroblasts [28].
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To determine the sequence of cytokine and lipid mediator activation within the
periodontium during experimental gingivitis, Heasman et al. [29] collected GCF from
healthy patients at baseline and weekly during four weeks of cessation of oral hygiene
measures. GCF samples were assayed for several mediators, including PGE2, IL-1 beta
and TNF-alpha. PGE-2 levels remained stable at baseline levels for the first three weeks
and then increased by 2.5-fold at four weeks. IL-1 beta levels increased significantly at
one week and remained at this heightened level for the duration of the study. These data
suggest IL-1 beta is involved in the earliest phases of gingivitis whereas PGE2 is
mediating the late response. TNF-alpha levels remained undetectable throughout this
study. In another study of native gingivitis, however, both IL-1 beta and TNF-alpha
levels in GCF were significantly higher in gingivitis subjects compared to periodontally
healthy patients [30].

The application of suspension bead multiplexing methods for the simultaneous analysis
of multiple inflammatory mediators has been used to characterize the levels of
inflammatory mediators associated with naturally occurring as well as experimental
gingivitis in humans [31, 32]. These studies have shown that chronic gingivitis is
associated with a 1.35-fold increase in IL-1 beta and a 2.1-fold increase in IL-6 in GCF
[31]. Gingivitis induction during an experimental gingivitis model was associated with a
2.6-fold increase in IL-1 beta and a 3.1-fold increase in IL-1 alpha. Interestingly, IL-8
decreased significantly in GCF during gingivitis induction and rebounded to baseline
during resolution [32].
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A study by Trombelli et al. [33] also evaluated IL-1 beta levels in GCF in naturally
occurring as well as experimentally induced plaque-associated gingivitis. Experimental
gingivitis was induced in one test quadrant while oral hygiene was continued in the
contralateral control quadrant. In experimental gingivitis, IL-1 beta levels were
significantly higher in test compared with control quadrants. Similar to the previously
mentioned studies, GCF IL-1 beta was significantly higher in experimentally induced
gingivitis sites compared to naturally occurring gingivitis sites. Higher IL-1 beta
concentrations observed in experimentally induced gingivitis may reflect the increased
microbial challenge to the gingival tissues associated with the experimental conditions of
plaque accumulation.

Other inflammatory mediators, such as IL-1 receptor antagonist (IL-1 ra), chemokine (CC motif) ligand 22 (CCL22) and growth-related oncogene (GRO), have been evaluated as
potential markers for periodontitis, but not gingivitis. IL-1 ra is significantly increased in
GCF from periodontitis patients compared to healthy controls, however this increased
secretion of IL-1 ra in periodontitis does not inhibit IL-1 beta release [34]. CCL22,
previously macrophage-derived chemokine, targets dendritic cells, NK cells and T cell
subsets. CCL22 is a potent attractant for Th2 cells [35]. Gingival biopsies from
periodontitis patients have greater CCL22 expression than biopsies from healthy patients
[36]. GRO, a PMN chemoattractant, is significantly increased in GCF from periodontitis
patients compared to healthy controls. However, no study has examined IL-1 ra, CCL22
and GRO in gingivitis.
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Overall, gingivitis involves inflammation of the gingival unit, without accompanying
bone destruction, as a result of the presence of pathogenic bacteria leading to increased
levels of inflammatory cytokines and tissue-destructive molecules.

1.3 Peri-implant mucositis
1.3.1 Microbiota changes in peri-implant mucositis
The microbiota of periodontal and peri-implant infections are largely similar. Implants
with clinical signs of peri-implantitis are associated with high counts and proportions of
gram-negative anaerobic bacteria. Diseased implant sites have demonstrated a high
prevalence of periodontal pathogens, including Porphyromonas gingivalis, Treponema
denticola, T. forsythia, Fusobacterium species, P. intermedia and Aggregatibacter
actinomycetemcomitans. However, some species not traditionally found in periodontitis
sites have been isolated at implant sites. Staphylococcus aureus, enteric rods and Candida
albicans have been isolated from sites with peri-implant disease [13].

Recently, pyrosequencing has been applied to the study of healthy and diseased periimplant microbiomes. In a study by Kumar et al. [37], subgingival and submucosal
plaque samples were collected from a total of 40 patients with periodontitis (n = 10), periimplantitis (n=10) and periodontal (n = 10) and peri-implant (n = 10) health and analyzed
using 16S pyrosequencing. Peri-implant sites demonstrated lower bacterial diversity than
both healthy and diseased subgingival sites. The predominant phylotypes in both healthy
and diseased peri-implant communities were members of the genera Butyrivibrio,
Campylobacter, Eubacterium, Prevotella, Selenomas, Streptococcus, Actinomyces,

12

Leptotrichia, Propionibacterium, Peptococcus, Lactococcus and Treponema. Lower
levels of Prevotella and Leptotrichia and higher levels of Actinomyces, Peptococcus,
Campylobacter, Streptococcus and Butyrivibrio were associated with diseased implants
compared to healthy implants. Peri-implant disease communities also demonstrated lower
levels of Prevotella, non-mutans Streptococcus, Lactobacillus, Selenomonas,
Leptotrichia, Actinomyces and higher levels of Peptococcus, Mycoplasma, Eubacterium,
Campylobacter, Butyrivibrio, Streptococcus mutans and Treponema than biofilms
associated with periodontitis. Therefore, it appears that discrepancies are present in the
phylotypes that colonize implant surfaces compared to teeth and different phylotypes are
implicated in native peri-implantitis versus periodontitis.

The majority of the limited research about the microbiota associated with peri-implant
infection is related to peri-implantitis rather than peri-implant mucositis. Since perimucositis is a precursor to the establishment of peri-implantitis, it is imperative to
elucidate the microbial profile present during this transitional step in the progression to
implant bone loss. In a combined experimental gingivitis and mucositis study by Salvi et
al. (2012), clinical, microbiological and host inflammatory markers were monitored
around teeth and implants. Fifteen subjects with healthy, restored implants underwent
three weeks of undisturbed plaque accumulation followed by three weeks of optimal
plaque control. The presence or absence of plaque deposits and gingival/mucosal
conditions were evaluated weekly. Microbial samples were analyzed using DNA-DNA
hybridization for 40 species. No differences in the total microbial DNA counts or
detection frequency for putative periodontal pathogens were found between implant and
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tooth sites at any time point. However, this study also did not find significant intrasubject changes in levels of specific microorganisms during the experimental period for
both implants and teeth [38]. In this design, sites were samples repeatedly over time,
potentially disturbing the biofilm and preventing recolonization, which may explain the
lack of difference between the groups. It should be noted that these results conflict with
previously mentioned studies that found variations in the microflora around implants and
teeth using different techniques.

In a split-mouth design study [39], the bacterial communities at implant and tooth sites
with native peri-implant mucositis or gingivitis, respectively, were compared via broadrange PCR followed by DNA fingerprinting and sequencing of plaque samples. This
technique does not provide information on abundance of taxa and is less comprehensive
than high-throughput sequencing, which is a limitation of this study. Samples from the
gingival sulci demonstrated significantly higher diversity than peri-implant samples.
Twelve bacterial genera, including Campylobacter and Neisseria, were not found at
implant sites but were frequently isolated at dental sites. In contrast, members of TM7
were detected solely at implant sites. Although the findings of the previously discussed
study oppose the findings of this study in terms of presence or absence of Campylobacter
at implant sites, the two studies are in agreement with respect to peri-implant microbial
diversity. The diversity of the microflora in sites demonstrating established periimplantitis or peri-implant mucositis seems reduced in comparison to that of periodontitis
or gingivitis [39]. Different microbiomes surrounding implants and teeth may thus affect
the mechanisms by which initial inflammatory lesions progress to irreversible changes.
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1.3.2 Host response in peri-implant mucositis
It has been proposed that peri-implant soft tissues may develop a stronger inflammatory
response to plaque accumulation than soft tissues around teeth. Biopsies harvested from
one tooth and one implant site in partially edentulous patients in health and after three
weeks of undisturbed plaque accumulation demonstrated a trend toward significantly
increased B and T cells in the peri-implant mucosa compared to the gingiva [8]. Similar
evidence was found in the Salvi et al. (2012) study. Weekly GCF samples were analyzed
for matrix metalloproteinase-8 (MMP-8) and IL-1ß levels. GCF levels of MMP-8, but not
IL-1ß, were significantly higher at implants compared with teeth over the six-week
experimental period. Three weeks after the reinstitution of oral hygiene, reversibility of
experimental gingivitis and mucositis was achieved at the biomarker level. Clinically,
gingival and peri-implant mucosal health were not achieved after three weeks of resumed
plaque control, suggesting that longer healing periods are required for both teeth and
implants [38].

In addition to MMP-8, other indicators of PMN function, such as lactoferrin and elastase,
have been identified as potential biomarkers for peri-implantitis. Lactoferrin, an ironbinding protein stored in secondary neutrophilic granules that are released during PMN
chemotaxis, is associated with the number of PMNs present in a lesion. Elastase, a serine
protease stored in primary neutrophilic granules, is released extracellularly during
phagocytosis and activation of PMNs and degrades collagen, laminin and fibronectin. In
a study that aimed to characterize the inflammatory host response around implants and
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teeth in patients with peri-implantitis, GCF samples were collected from implants with
peri-implantitis, stable implants in patients with both stable and peri-implantitis implants
and control implants in patients with stable implants only [12]. In patients with periimplantitis, lactoferrin concentration was higher at implants with peri-implantitis than at
stable implants. Elastase activity was higher at implants with peri-implantitis compared to
stable implants in controls. Therefore, lactoferrin concentration and elastase activity in
crevicular fluid are markers of site-specific inflammation, specifically PMN activation,
around dental implants.

The neutrophilic enzyme myeloperoxidase (MPO) is a heme-containing enzyme with
non-specific peroxidase activity, enabling oxidation of a wide range of substrates. In the
presence of hydrogen peroxide and chloride ions, MPO catalyzes the oxidation of Cl- into
hypochlorous acid, which kills many bacterial and fungal species in vitro. It has been
demonstrated that total amounts of MPO are significantly higher in the peri-implant
sulcular fluid surrounding implants with peri-implantitis or peri-implant mucositis
compared to that of healthy implants. Also, MPO activity increases with increasing
pocket probing depth (PPD), gingival index (GI) and bleeding on probing (BOP) scores.
Therefore, MPO could be an important marker for peri-implant mucositis and periimplantitis [40].

Since little is known about the host response during peri-implant mucositis, the host
responses around teeth and implants in health and during periodontitis/peri-implantitis
may provide a foundation for understanding peri-implant mucositis. Implant sites
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demonstrate higher concentrations of inflammatory cytokines such as IL-8 and TNFalpha [11]. A recent study compared the histology of periodontitis and peri-implantitis
lesions in 40 patients with generalized severe chronic periodontitis and 40 patients with
severe peri-implantitis. Peri-implantitis biopsies demonstrated significantly larger
infiltrated connective tissue areas compared to periodontitis samples. In addition, periimplantitis lesions contained significantly larger area proportions and densities of
CD138-, CD68- and MPO-positive cells than periodontitis lesions [41].

In summary, the results of these studies demonstrate that there are dissimilarities in the
host responses around implants evidenced as significant differences in histopathology and
inflammatory markers measured in GCF. Most studies suggest an exacerbated response
around implants in comparison to teeth.

1.4 Rationale for this study
Overall, the microbiome and host response associated with peri-implant mucositis are not
fully understood. Although there are data suggesting that, compared to either
periodontitis or gingivitis, peri-implant lesions demonstrate decreased microbial diversity,
differences in the presence and prevalence of certain bacteria and an increased response
from host inflammatory proteins, it is yet to be determined whether peri-implant
mucositis processes closely mimic those of gingivitis.

To the extent that peri-implant mucositis and gingivitis differ in associated microbiomes
and/or host response, clinical approaches to diagnosis, prevention and therapy may also
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differ. As the gateway lesion to peri-implantitis, peri-implant mucositis represents a
critical step in avoiding implant failure. Therefore, understanding characteristics of the
microflora in health and initial disease, as well as destructive host inflammatory and
immune response to bacterial pathogens, can guide research and the management of
implants.

Most studies to date have examined peri-implantitis rather than its precursor, peri-implant
mucositis. In the natural dentition, understanding the development of salient disease,
periodontitis, derives from the characterization of its precursor, gingivitis. Similarly, our
grasp of peri-implantitis must be based on a more detailed examination of peri-implant
mucositis. The dramatic distinctions between implants and teeth, for example in
molecular composition (titanium versus enamel), physical (especially surface and
anatomical) qualities, histological attachment mechanisms, blood supply and mode of
establishment in the mouth (eruption versus surgical insertion), raise the possibility that
the bacterial species and communities associated with implants may have limited
resemblance to those associated with teeth. These microbial differences, and such unique
features as lack of periodontal ligament and reduced vascularity, could lead to variations
in host response during initiation and progression of disease.

The present study aims to further characterize the evolution of the whole microbial
profile and the associated changes in host response at teeth and implant sites in three
phases: during a native condition, a 21-day period of oral hygiene cessation and after
resumption of oral hygiene practices.
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1.5 Hypothesis
For the above-mentioned reasons, we hypothesize that the microbial and immune
responses differ between implants and teeth during native and experimental peri-implant
mucositis/gingivitis and after peri-implant mucositis/gingivitis resolution.

2. Objectives
2.1. Specific aims
Aim 1. To cross-sectionally compare the microbial biofilms and GCF
inflammatory markers between teeth and dental implants in their native state
Aim 2. To longitudinally evaluate the changes in the microbial flora and GCF
inflammatory markers during 21 days of de novo plaque accumulation around dental
implants in comparison to teeth
Aim 3. To compare the immunological and microbiological responses after oral
hygiene measures are resumed around dental implants and teeth

3. Study design and methods
This is a controlled clinical trial to compare the responses to de novo plaque
accumulation in peri-implant soft tissue and gingiva within subjects (n=15). We
evaluated immunological and microbiological parameters at a baseline native state, over
21 days of experimental peri-implant mucositis/gingivitis and following reinstitution of
oral hygiene practices. To achieve the previously mentioned objectives, we collected
GCF and biofilm samples from two Straumann implants and two natural teeth in
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systemically healthy patients. Host inflammatory markers were analyzed via ELISA and
Luminex technology. The microbiome composition of the plaque samples was
determined by high-throughput sequencing of the bacterial 16S rRNA gene.

3.1 Study population
Eighteen voluntary participants were recruited among the patient population formerly
treated with implant therapy at the University of Connecticut, School of Dental Medicine.
Table 1 shows the inclusion and exclusion criteria for this study.

Table 1. Inclusion and exclusion criteria
Inclusion criteria
• ≥21 years of age;
• Presence of 2 implants in the maxillary or
mandibular arch supporting fixed
restorations in function for at least 1 year
(Test);
• Presence of 2 teeth in the corresponding
position of the implant (Control);
• Absence of active infections at both test and
control sites
• Absence of radiographic bone loss at both
test and control sites
• Pocket depth ≤4mm at both test and control
sites
• Must give written informed consent.

Exclusion criteria
• Treatment with antibiotics for any dental or
medical condition within 1 month before
screening;
• Systemic diseases that require chronic use
of anti-inflammatory medications,
antibiotics or anticoagulants;
• Ongoing medications for systemic
conditions initiated <3 months before the
start of the study or the requirement to take
prophylactic antibiotics for invasive dental
procedures;
• Significant organ disease including
impaired kidney function, heart murmur,
rheumatic fever, bleeding disorder;
• Active infectious diseases such as hepatitis,
tuberculosis and HIV;
• Clinically detectable caries and/or
periodontal disease;
• Tobacco use of any kind;
• Use of medications affecting periodontal
status (diphenylhydantoin, cyclosporine,
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etc.)
• No pregnancy or lactation or expectation to
become pregnant within next 3 months.

3.2 Clinical study design
This is a controlled cross-arch study. The test site included two Straumann Tissue Level
implants supporting fixed restorations in function for at least one year. The control site
included two teeth in the corresponding position of the implants. Subjects were seen at a
screening visit and at a “pre-experimental phase” visit to collect information on naturally
occurring gingivitis and peri-implant mucositis if present. After prophylaxis to achieve
optimal gingival and mucosal health, a customized stent was given to subjects to wear
during toothbrushing and flossing on test and control sites to prevent daily plaque
removal from these areas. Oral hygiene procedures were resumed after 21 days of plaque
accumulation. Clinical parameters were measured and saliva, GCF and biofilm samples
were obtained weekly for the duration of the study (Figure 1).
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Figure 1. Experimental design and procedures. GI, modified plaque index (PlI) and
angulated bleeding score (ABS) were recorded. GCF samples were collected for GCF
flow determination and host marker evaluations. Microbial sampling was also performed
Blood and saliva samples were stored at -80°C for future analysis.

3.3 Clinical study procedures and sample collection
3.3.1 Informed consent
During the screening visit, the experimental procedure was explained and a written
informed consent was presented to the patient. Inclusion and exclusion criteria were
verified.

3.3.2 Vitamin C administration
To prevent subclinical vitamin C deficiency that could affect susceptibility to
inflammation, eligible subjects received a supply of vitamin C supplement (250 mg/day)
to take for the 56-day pre-trial and trial period.

3.3.3 GCF flow rate
For determination of GCF flow rate, GCF was collected for 5 seconds from the mesial
and buccal surfaces of the most posterior teeth and implants and measured according to
Periotron 8,000 manufacturer’s instructions (OraFlow Inc., Plainview, NY, USA).
Following isolation of the site with cotton rolls, a Periopaper strip was inserted 1-2 mm
subgingivally into the gingival sulcus.
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3.3.4 Collection of GCF for host marker evaluation
GCF was also collected for host marker evaluation. GCF was collected for 30 seconds
from the mesial and buccal surfaces of the most anterior teeth and implants. Samples
were placed on ice, transported to the lab and stored at -80°C.

3.3.5 Clinical exam
GI was recorded on the mesial and buccal surfaces of teeth and implants using the Silness
and Löe (1964) [42] method without the bleeding component, according to the
modification described by Trombelli et al. (2004) [43]. Plaque Index (PlI) on mesial and
buccal surfaces of teeth and implants was measured using the Silness and Löe (1964)[67]
method and recorded according to Furuichi et al. (1992)[44]. ABS, according to the
modification of the score by van der Weijden et al. (1994)[45], was recorded on the
mesial and buccal surfaces of teeth and implants.

3.3.6 Biofilm collection
Biofilm samples were collected at the distal surfaces of the most posterior implant and
tooth for visits 1, 3, 5 and 7. For visit 4, plaque was collected from the distal surfaces of
the most anterior implant and tooth. A plastic curette was inserted into the sulcus and the
biofilm was removed by a single stroke. The sample was placed into a 50µl Tris-EDTA
(TE) buffer solution, which was stored at -80°C until further microbiological analysis.

3.3.7 Stent fabrication
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An alginate impression was made for fabrication of the stent necessary to prevent
disturbance of plaque accumulation during oral hygiene procedures.

3.3.8 Oral hygiene and prophylaxis during visits 1 and 2
Oral hygiene instruction (OHI) was provided to subjects. A toothbrush, floss and nonfluoridated toothpaste were distributed to each participant and participants were
instructed to abstain for mouth rinse use during the study. Patients also received full
mouth scaling and polishing during visit 1. If GI did not equal zero on visit 2, another
session of scaling, polishing and OHI was provided prior to proceeding with the protocol.
Lastly, patients were provided with the stent and instructed to wear it for 21 days during
oral hygiene practices.

3.3.9 Colgate Total® toothpaste administration and reinstitution of oral hygiene
At the end of visit 6 (day +21), OHI was given and subjects returned the stent and
reinstituted oral hygiene practices. Subjects were provided with Colgate Total®
toothpaste to be used daily. In the final visit, subjects were given OHI and scaling and
polishing were also provided.

3.3.10 Exam and sample collection sequence
During each visit, GI was recorded first. Second, GCF was collected for GCF flow rate
determination and host marker evaluation. Paper strips contaminated with saliva and/or
blood were discarded. Then biofilm samples were obtained. Following GCF and biofilm
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sample collection, ABS was measured. Lastly, plaque was stained with disclosing
solution, if require, and PlI was recorded.

3.4 Microbiological laboratory procedures
DNA was isolated from individual plaque samples and quantified. Total microbial load
was determined via quantitative real time PCR. Microbiome composition of the samples
was determined via high-throughput sequencing of the 16S rRNA gene using the Illumina
MiSeq platform [46].

3.4.1 DNA isolation
Plaque samples were collected and placed in 50 µl of TE buffer. Samples were resuspended in lysis buffer with lysozyme at 37°C for 30 minutes. Next, AL buffer and
proteinase K (Qiagen DNA extraction kit) were added and the suspension was incubated
at 56°C overnight. Samples were then incubated at 95°C for 5 minutes to inactivate
proteinase K. DNA isolation was performed using a commercially available kit according
to the instruction of the manufacturer (Qiagen DNeasy Blood and Tissue kit). DNA was
eluted in 50 µl of MD5 solution (MoBio Laboratories) and its concentration was
measured using a NanoDrop instrument (ThermoScientific). A positive control (180 µl of
a known bacterial culture) was included to verify technique performance and a negative
control (180 µl of lysis and TE buffers without any sample) was included for the
assessment of sample contamination by foreign DNA.

3.4.2 Subgingival bacterial load quantification by real time PCR
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The determination of the subgingival bacterial load of plaque samples was performed via
real-time PCR using a TaqMan probe (Table 2) and universal 16S rRNA primers (Table 3)
[47]. Samples were analyzed in singlicate in 96-well plates with a CFX96 Real-time
system C1000 Thermocycler (BioRad). Standard curves were generated using DNA from
serial dilutions of a pure culture of F. nucleatum.
Table 2. TaqMan probe [47].
(6-FAM)-5’-CGTATTACCGCGGCTGCTGGCAC-3’-(TAMRA)
Table 3. Universal primers used to determine subgingival bacterial load [47].
Forward: 5’-TCCTACGGGAGGCAGCAGT-3’
Reverse: 5’-GGACTACCAGGGTATCTAATCCTGTT-3’
Each reaction was performed in a total volume of 50 µl containing 25µl TaqMan Master
Mix, 5 µl of each forward and reverse primer, PCR water (9 µl for plaque samples; 5 µl
for standard curve), and 1 µl plaque DNA sample or 5µl of diluted DNA from F.
nucleatum for standard curves. The qPCR cycle consisted of 95°C for 10 minutes,
followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. The
quantification of subgingival bacterial load was calculated using qPCR software (CFX
Manager, Bio-Rad) and F. nucleatum standard curve with known 16S rRNA copy
number.

3.4.3 Microbiome determination
Amplicon libraries were prepared using fusion primers with adaptor, indices, spacer and
primers. Tables 4-6 list fusion primers used for MiSeq sequencing. Figures 2 and 3
provide schematic representations of the fusion primers and sequencing strategy,
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respectively. These primers amplify a 423 bp region of the 16S rRNA gene spanning V1
and V2, the hypervariable regions that perform best in the assignment of species
taxonomy to short sequence reads [48].
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Table 4. Forward and reverse adaptor sequences used in fusion MiSeq primers.
Forward and reverse adaptor sequences
5’-CAAGCAGAAGACGGCATACGAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3’
5’- AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT-3’

Table 5. Sequences of universal primers used in fusion MiSeq primers.
Universal primers
Forward 5’-AGAGTTTGATCMTGGCTGAC-3’
Reverse 5’-CYIACTGCTGCCTCCCGTAG-3’

Table 6. Forward indices used

Table 7. Reverse indices used

in MiSeq primers.

in Miseq primers.

Forward indices

Reverse indices

GTGGTATGGGAG
ACTTTAAGGGTG
GAGCAACATCCT
TGTTGCGTTTCT
ATGTCCGACCAA
AGGTACGCAATT
ACAGCCACCCAT
TGTCTCGCAAGC
GAGGAGTAAAGC
GTTACGTGGTTG
TACCGCCTCGGA
CGTAAGATGCCT
TACCGGCTTGCA
ATCTAGTGGCAA
CCAGGGACTTCT
CACCTTACCTTA
ATAGTTAGGGCT
GCACTTCATTTC

TGCAGATCCAAC
CCATCACATAGG
GTGGTATGGGAG
ACTTTAAGGGTG
ATGTCCGACCAA
AGGTACGCAATT
ACAGCCACCCAT
TGTCTCGCAAGC
GAGGAGTAAAGC
GTTACGTGGTTG
TACCGCCTCGGA
CGTAAGATGCCT
TACCGGCTTGCA
ATCTAGTGGCAA
CCAGGGACTTCT
CACCTTACCTTA
ATAGTTAGGGCT
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Figure 2. Fusion primers designed for bidirectional sequencing using the MiSeq Illumina
platform. Primers included 5’ and 3’ adaptor sequences, index 1 and 2, heterogeneity
spacers, forward and reverse 16S rRNA gene universal primers and bacterial template.
Indices served to tag each sample, allowing for massive parallel sequencing.
Heterogeneity spacers were 0 to 7 bp sequences implemented to introduce library
diversity.

Figure 3. Sequencing strategy. A 528 bp amplicon was generated and sequenced
bidirectionally with the MiSeq Reagent Kit v3 (300 cycles). A 150 bp overlap was
expected after assembling the forward and reverse reads.
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PCR was performed in thin-walled tubes with a C1000 Touch Thermocycler (BioRad,
Hercules, CA). Each reaction was performed in triplicate using a total volume of 20 µl
containing 10.5 µl water, 1.2 µl forward primer, 1.2 µl reverse primer, 0.4 µl 10mM
dNTPs, 0.6 µl 50mM MgSO4, 0.125 µl Platinum Taq polymerase and 2 µl 10X buffer.
Thermal cycler conditions were as follows: pre-heating of samples at 95°C for 3 minutes
followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at 50°C for 30
seconds, and elongation at 72°C for 60 seconds. This was followed by a final elongation
step at 72°C for 9 minutes. Reaction products were evaluated by gel electrophoresis (1.5%
agarose gel run at 100V for 20 minutes), DNA was stained using ethidium bromide and
visualized under short-wavelength UV-light (Gel-Doc system, BioRad). The AmpureXP
bead was used to purify PCR products and select fragments of a size greater than 300 bp.
Finally, amplicon library quantification analysis was conducted using Qubit (Life
Technologies) and bacterial amplicon libraries were sequenced with Illumina MiSeq V3
chemistry (MiSeq Sequencer). For this, the sample library and 20% PhiX were denatured
and loaded to the flow cell.

3.4.4 Processing and analysis of bacterial sequences
Sequences obtained from MiSeq were processed using the mothur software [49]. Forward
and reverse sequence reads were trimmed using a sliding window strategy by quality
score (Q30 > 35) and a window size of 50 bp. Forward and reverse reads were then
assembled. Primers and indices were trimmed and sequences filtered to exclude
sequences with ambiguous base calls and read lengths less than 200 bp and 400 bp.
Unique sequences were aligned using the SILVA database as a reference [50] and ends
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trimmed such that sequences only included a comparable anchor region. Sequences were
further processed by a modification of the single linkage algorithm [51,53] to determine
sequences with up to 2 bp difference from a more abundant sequence and merge their
counts, which reduces variability thereby reducing errors caused by sequencing. Chimeric
sequences were then removed by applying the UChime algorithm [53] as implemented in
mothur. Next, a distance matrix was produced and sequences were clustered into OTUs
based on a 3% difference [54]. Classification of sequences was performed using the
Ribosome Database Project (RDP) classifier with the RDP reference trainset [55] or the
Human Oral Microbiome Database (HOMD) trainset (www.homd.org) as templates.
OTUs were classified according to the majority taxonomic assignments for reads in each
OTU. If a taxonomic assignment at the species level was not possible, the most abundant
sequence from each OTU was compared by Blast to the HOMD. In cases of more than 97%
homology of the representative sequence to an HOMD reference sequence, the HOMD
match was also included in parenthesis as part of the OTU taxonomy.

Alpha diversity analysis comprised richness, evenness and total diversity. Richness was
assessed by evaluation of the number of observed OTUs. Evenness was obtained using
the Shannon evenness index. Total diversity was evaluated by the inverse of the Simpson
Index and the non-parametric Shannon index [56-58]. Beta diversity was measured with
the Theta YC distance [59] for comparison of communities based on structure. PCoA was
performed in mothur and graphs were visualized using rgl application in R (http://www.rproject.org).
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3.5 Host inflammatory marker analysis
GCF volume was measured with the Periotron 8000 (OraFlow Inc., Plainview, NY), as it
has been shown to correlate with peri-implant and gingival inflammation [43]. The site
was first isolated with cotton rolls to prevent contamination with saliva. Then a
Periopaper strip was gently inserted 1-2 mm into the gingival sulcus by a calibrated
examiner for 5 seconds for GCF volume measurement or 30 seconds for host marker
evaluation. Samples contaminated with blood were discarded. Functional activation of
PMNs was assessed by MPO and lactoferrin GCF levels as described below. MPO was
assayed as representative of neutrophilic oxidative killing mechanisms. Lactoferrin was
measured as representative of non-oxidative killing mechanisms. GCF levels of IL-1
alpha, IL-1 beta, IL-1 ra, IL-8, TNF-alpha, CCL22 and GRO (alpha, beta and gamma)
were quantified with a multiplex assay, allowing for simultaneous cytokine quantification
(EMD Millipore, Billerica, MA).

3.5.1 Lactoferrin and MPO quantification in GCF
MPO and lactoferrin in GCF were quantified by enzyme-linked immunosorbent assay
(ELISA). Elution buffer was prepared with 0.05% Tween 20, 1 mg/ml BSA in PBS with
complete proteinase inhibitor (Roche Life Science, Indianapolis, IN) and filtered with
0.22 µm pore size syringe filter. Each paper strip was eluted with 60 µl of elution buffer,
vortexed and stored overnight at 4°C. Then samples were vortexed, briefly centrifuged so
that all elution buffer remained in the bottom of the eppendorf tube and both the eluted
paper strips and GCF samples were transferred to new eppendorf tubes separated by a
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basket. Samples were then centrifuged at 13,000 rpm for 10 minutes. Eluted samples
were then diluted. Optimal dilutions for lactoferrin and MPO were determined after pilot
trials.

Lactoferrin ELISA was performed with a commercially available kit according to the
instructions of the manufacturer (Abcam, Cambridge, MA). Fifty µl of the GCF samples
diluted by 1:500 were added to 96 wells that were precoated with a lactoferrin-specific
antibody and incubated for two hours. Subsequently, a lactoferrin-specific biotinylated
detection antibody was added, incubated for one hour and washed with wash buffer.
Streptavidin-peroxidase conjugate was added, incubated for 30 minutes and unbound
conjugates were washed away with wash buffer. Chromogen substrate was then used to
visualize the streptavidin-peroxidase enzymatic reaction. This substrate produced a blue
color product that changed to yellow after adding acidic stop solution. The absorbance
was read on a microplate reader at a wavelength of 450 nm.

A similar assay was completed for MPO quantification (R & D, Minneapolis, MN). An
MPO-specific mouse monoclonal antibody was precoated on 96-well plates. Standards
and test samples diluted by 1:2000 were added to the wells and incubated. The
biotinylated detection MPO-specific goat polyclonal antibody was added followed by
washing. Avidin-Biotin-Peroxidase Complex was added and incubated. Subsequently,
TMB was used to visualize the enzymatic reaction and absorbance was read on a
microplate reader. Target concentrations for MPO and lactoferrin were calculated with a
four-parameter logistic equation using SOFTmax Pro software (Sunnyvale, CA).
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3.5.2 IL-1 alpha, IL-1 beta, IL-1 ra, IL-8, TNF-alpha, GM-CSF, CCL22 and GRO
quantification in GCF
IL-1 alpha, IL-1 beta and IL-1 ra, IL-8, TNF-alpha, GM-CSF, CCL22 and GRO (alpha,
beta and gamma) in GCF were analyzed by multiplex assay, allowing for simultaneous
quantification of multiple cytokines (EMD Millipore). After a pilot trial, it was
determined that IL-1 ra required a 1:10 dilution. Samples for other cytokines were not
diluted. For multiplex cytokine detection, microspheres coated with fluorescent dyes and
specific capture antibodies were added to the sample. After the bead captured an analyte
from the test sample, a biotinylated detection antibody was introduced and the reaction
mixture was incubated with streptavidin conjugate (reporter molecule) to complete the
reaction on the surface of each microsphere. Samples were passed through a primary
laser, exciting the dyes to mark the microsphere, and then passed through a secondary
laser, exciting the fluorescent dye on the reporter molecule. High-speed digital-signal
processors identified each microsphere and quantified the result of its bioassay based on
the fluorescent reporter signals (Luminex 200). Target concentrations were calculated
with a four-parameter logistic equation using SOFTmax Pro software (Sunnyvale, CA).

3.6 Statistical analysis
Clinical microbiological and host inflammatory marker assessments were performed
across groups for Aims 1 and 3. For Aims 2 and 3, both within group and across group
comparisons were performed. Statistical significance was considered when p values were
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<0.05 and below the threshold determined by multiple testing using the BenjaminiHochberg false discovery rate method.

Paired-sample Wilcoxon Signed-Rank tests were employed to assess differences in
clinical parameters, host inflammatory markers, subgingival bacterial load, alpha
diversity and OTU abundance. For comparisons of OTU relative abundance, only those
OTUs with at least 0.1% relative abundance in at least one sample were considered (533
OTUs). Significant separation of clusters after PCoA analysis was evaluated via analysis
of molecular variance (AMOVA) [60]. Bivariate Spearman’s Rank-Order Correlation
tests were used to evaluate correlation of clinical, host and microbiological variables in
implant and teeth sites (between group correlations), to evaluate the correlation among all
variables within a group (within group correlations) and to evaluate the correlation of
OTU relative abundance with Principal Component 1 in PCoA plots.

4. Results
4.1 General considerations
Clinical results were presented in a thesis by Dr. Jonah Barasz and have been updated for
this thesis (Figure 4). Fifteen patients out of 18 enrolled completed the trial. One patient
was excluded from the study when suppuration of the mucosal margin at a test site was
observed at visit 5 (day 14). The site was treated with debridement, irrigation and 0.12%
chlorhexidine rinse for seven days. The condition resolved completely after seven days.
Two subjects exited the study due to changes in medical condition unrelated to the study
proceedings prior to visit 1 (day -14) and visit 2 (day -7). Figures 5, 6, and 7 present
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results of inflammatory mediator assays. GM-CSF was not included because it was nondetectable in most samples. Subgingival bacterial load measurement via qPCR is shown
in Figure 8. Microbiome sequencing yielded 11,167,919 sequences after preprocessing,
with an average of 27,674 sequences per sample. The range of sequences per samples
was 13 to 53,374, however. Since comparison among samples requires the same number
of reads, samples were subsampled to contain 5,298 sequences. This excluded 13 samples
from the analysis (visit 1 for subjects 11 (control), 14 (control and test) and 17 (control);
visit 3 for subjects 2 (test), 4 (test), 14 (test), 17 (control and test) and 18 (control); visit 4
for subject 7 (test); visit 7 for subjects 5 (test) and 16 (control)).
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Figure 4. Clinical response of teeth and implants during the trial. Box plots show GCF
volume (a), GI (b), PlI (c) and ABS (d) in test (implants) and control (teeth) sites during
study visits. Within group comparisons are shown in tables below the graphs. Across and
within group differences at each time point are indicated by asterisks. * = p<0.05; ** =
p<0.01
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Figure 5. Inflammatory response of teeth and implants during the trial. Box plots show
lactoferrin (LF; a), MPO (b), IL-8 (c) and CCL22 (d) concentrations in test (implants)
and control (teeth) sites during study visits. Within group comparisons are shown in
tables below the graphs. Across and within group differences at each time point are
indicated by asterisks. * = p<0.05
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Figure 6. Inflammatory response of teeth and implants during the trial. Box plots show
IL-1 alpha (a), IL-1 beta (b), IL-1 ra (c) and TNF-alpha (d) concentrations in test
(implants) and control (teeth) sites during study visits. Within group comparisons are
shown in tables below the graphs. Across and within group differences at each time point
are indicated by asterisks. * = p<0.05; ** = p<0.01
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Figure 7. Inflammatory response of teeth and implants during the trial. Box plot shows
GRO concentration test (implants) and control (teeth) sites during study visits. Within
group comparisons are shown in tables below the graph. * = p<0.05
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Figure 8. Microbiological response of teeth and implants during the trial. Box plot shows
subgingival bacterial load in test (implants) and control (teeth) sites during study visits.
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Within group comparisons are shown in table below the graph. Across and within group
differences at each time point are indicated by asterisks. * = p<0.05; ** = p<0.01
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Figure 9. Microbiological response of teeth and implants during the trial. Box plots
shows alpha diversity, as measured by richness (a), evenness (b), non-parametric
Shannon Index (c) and Inverse Simpson Index (d), in test (implants) and control (teeth)
sites during study visits. Within group comparisons are shown in tables below the graphs.
Across and within group differences at each time point are indicated by asterisks. * =
p<0.05; ** = p<0.01
41

4.2 Results related to Aim 1
The first aim of this thesis (Aim 1) was to cross-sectionally compare the microbial
biofilms and GCF inflammatory markers between teeth and implants at the baseline visit
(day -14), assuming this visit represents the native state ranging from health to gingivitis
or peri-implant mucositis.

4.2.1 Clinical results
On day -14, GI was significantly higher at teeth compared to implants (Figure 4b). There
were no significant differences in GCF volume, PlI or ABS, however (Figure 4a, c, d).

4.2.2 GCF inflammatory marker results
Although GI, a marker for clinical inflammation, was higher in teeth than implants on
day -14 and ABS, GCF volume and PlI did not differ between groups, implants
demonstrated significantly higher concentrations of lactoferrin (Figure 5a), IL-1 ra
(Figure 6c) and TNF-alpha (Figure 6d) compared to teeth. There was also a trend for
higher MPO (Figure 5b), CCL22 (Figure 5d), IL-1 alpha (Figure 6a), IL-1 beta (Figure
6b), IL-8 (Figure 5c) and GRO (Figure 7) concentration at implants compared to teeth at
this time point. These results suggest that implants demonstrate higher inflammation at
the molecular, but not clinical, level than teeth during the native state.

4.2.3 Microbiological results
There were no significant differences in subgingival bacterial load (Figure 8) or alpha
diversity, as measured by richness (Figure 9a), evenness (Figure 9b), non-parametric
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Shannon Index (Figure 9c) and Inverse Simpson Index (Figure 9d) between implants and
teeth. Although implants and teeth had equal microbial load, as measured by PlI and 16S
rRNA copy number, and teeth had increased clinical inflammation, as measured by GI,
implants demonstrated higher concentrations of pro-inflammatory cytokines than teeth
during the native state.

On day -14, PCoA of distance among samples based on an ecology metric that takes into
account OTU presence and proportions (Theta YC) revealed no differences between teeth
and implants on day -14, suggesting that community structure in teeth and implants is the
same in the native condition (Figure 10).

Figure 10. PCoA plot of community structure (Theta YC) in teeth and implants on day 14. Gray = teeth; black = implants.

43

Prior to adjusting for multiple comparisons, the relative abundances of
Propionibacterium propionicum (p<0.05), C. gracilis (p<0.05), Capnocytophaga sp.
(HOT336; p<0.05), Selenomonas sputigena (p<0.05) and A. gerencseriae (p<0.05) were
significantly greater in teeth than implants (Figure 11). On the other hand,
Pasteurellaceae sp. (Terrahaemophilus aromaticivorans HOT826; p<0.05), Prevotella
melaninogenica (p<0.05) and Prevotella salivae (p<0.05), were significantly greater in
implants than teeth (Figure 11). However, after adjusting for multiple comparisons, there
were no significant differences in relative abundance of any of the OTUs between
implants and teeth at this time point.

Propionibacterium propionicum
Campylobacter gracilis
Capnocytophaga sp. (HOT336)
Selenomonas sputigena

Teeth
Implants

Actinomyces gerencseriae
Prevotella salivae
Prevotella melaninogenica

0.2
0.2
0.4
0.6
0.8

0.1

0.0

Pasteurellaceae sp. (Terrahaemophilus aromaticivorans HOT826)

Relative abundance (x100) day -14

Figure 11. Relative abundances of OTUs that were statistically significantly different
between teeth and implants on day -14 prior to adjusting for multiple comparisons. Bars
represent range of relative abundance values.

4.3 Results related to Aim 2
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The second aim of this thesis (Aim 2) was to longitudinally evaluate the changes in the
microbial flora and GCF inflammatory markers during 21 days of de novo plaque
accumulation around dental implants in comparison to teeth.

4.3.1 Clinical results
At baseline (day 0), GI (Figure 4b), PlI (Figure 4c) and ABS (Figure 4d) values were zero
for both teeth and implants, indicating absence of clinical signs of inflammation. During
the experimental phase, both teeth and implants accumulated plaque and developed
clinical signs of inflammation, peaking at day 21 (Figure 4). GCF volume (Figure 4a), GI
(Figure 4b), PlI (Figure 4c) and ABS (Figure 4d) were significantly higher on day 21
compared to day 0 for both teeth and implants. However, teeth and implants showed
differences in terms of plaque accumulation, with implants accumulating less plaque
during the experiment (Figure 4c). Consistent with this, GI tended to be lower in implants
than in teeth at all time points during the experimental period, although these differences
did not reach statistical significance. Interestingly, despite lower GI in implants, GCF
volume was higher in implants when compared to teeth on day 7 of the experimental
phase. This trend was also observed on day 14. ABS values did not differ statistically
between teeth and implants but there was a trend for higher ABS in implants compared to
teeth during experimental plaque accumulation.

4.3.2 GCF inflammatory marker results
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The decrease in plaque accumulation and clinical inflammation from day -14 to day 0
corresponded with lower concentrations of several of the inflammatory markers. Only IL1 ra (Figure 6c) was significantly lower on day 0 compared to day -14 for both teeth and
implants. For implants only, the absence of plaque on day 0 resulted in decreased
lactoferrin (Figure 5a) and GRO (Figure 7) compared to day -14. For teeth only, IL-1
alpha (Figure 6a) and IL-1 beta (Figure 6b) were significantly reduced on day 0
compared to day -14.

As plaque accumulation and clinical signs of inflammation increased over the
experimental phase, many of the inflammatory markers also increased. Members of the
IL-1 cytokine family seemed to be the most consistent biomarkers for plaque
accumulation around both implants and teeth (Figure 6). IL-1 alpha (Figure 6a), IL-1 beta
(Figure 6b) and IL-1 ra (Figure 6c) demonstrated significantly greater concentration at
day 21 compared to day 0 for both implants and teeth. The PMN activity marker
lactoferrin (Figure 5a), and to a lesser extent MPO (Figure 5b) and the chemokine IL-8
(Figure 5c), marked experimental gingivitis but not peri-implant mucositis; whereas
CCL22 (Figure 5d) was a marker for experimental peri-implant mucositis only. TNFalpha (Figure 6d) and GRO (Figure 7) concentrations did not change significantly
throughout the experimental period for either teeth or implants.

Across group comparisons showed that on day 7, IL-1 ra (Figure 6c) was significantly
higher at implants compared to teeth. On day 14, TNF-alpha (Figure 6d) was
significantly higher at implants compared to teeth. On day 21, TNF-alpha (Figure 6d) and
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CCL22 (Figure 5d) were significantly higher at implants compared to teeth. These results
are consistent with the trend for implants to display higher levels of inflammatory
markers than their teeth counterparts. However, there were no significant differences in
lactoferrin (Figure 5a), MPO (Figure 5b), IL-8 (Figure 5c), IL-1 alpha (Figure 6a), IL-1
beta (Figure 6b) and GRO (Figure 7) between implants and teeth during the experimental
phase.

The subject-specific magnitude of change in concentrations of inflammatory markers
over the experimental phase was also evaluated. Deltas were calculated by subtracting the
earlier visit value from the later visit value. The deltas from day 0 to 7 for IL-1 alpha, IL1 beta and TNF-alpha were significantly greater for teeth compared to implants (p<0.05).
The delta from day 0 to 14 for MPO was significantly greater for teeth compared to
implants (p<0.05). These results suggest a greater early response for these biomarkers in
teeth compared to implants.

In summary, IL-1 alpha, IL-1 beta and IL-1 ra were biomarkers for plaque accumulation
around both teeth and implants. Lactoferrin was a marker of experimental gingivitis but
not of peri-implant mucositis while CCL22 was a marker for experimental peri-implant
mucositis only.

4.3.3 Microbiological results
As expected from the PlI results, subgingival bacterial load at teeth and implants was
significantly lower on day 0 compared to day -14 (Figure 8). Subgingival bacterial load
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increased significantly over the experimental phase, with a dramatic difference between
day 0 and day 21 for both teeth and implants (Figure 8). None of the measures of alpha
diversity were different on day 0 compared to day -14 for teeth or implants, however.
Richness (Figure 9a), evenness (Figure 9b) and non-parametric Shannon Index (Figure 9c)
increased from day 0 to day 21 for teeth but not implants. The Inverse Simpson Index did
not differ throughout the experimental phase for teeth or implants. In accordance with the
PlI results, subgingival bacterial load was significantly greater in teeth than implants on
day 14 (Figure 8). There was no significant difference in alpha diversity (Figure 9)
between implants and teeth during the experimental phase.

The magnitude of the change in subgingival bacterial load and alpha diversity over the
experimental phase were also compared between teeth and implants. The delta from day
0 to 14 for subgingival bacterial load was significantly greater for teeth compared to
implants (p<0.05).

PCoA revealed a significant difference in community structure on day 0 compared to day
7 (p<0.01) and day 0 compared to day 21 (p<0.01) for teeth, such that there was a shift
along axis 1 as plaque accumulated. A similar trend, but not statistically significant, was
observed from day 0 to 14. Since axis 1 captured most of the variability during
experimental plaque accumulation in teeth, we then explored which OTUs correlated
with PC1. Figures 12-14 show that Veillonella parvula and R. dentocariosa were
correlated with PC1 from day 0 to 7, R. dentocariosa was correlated with PC1 from day 0
to 14 and F. nucleatum ss. animalis and R. dentocariosa were correlated with PC1 from
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day 0 to 21. The shift along axis 1 comparing day 0 to 7 in teeth was positively correlated
to V. parvula (r=0.76, p<0.01) and negatively correlated with R. dentocariosa (r=-0.78,
p<0.01), suggesting that V. parvula may drive the shift in community structure during the
first week of plaque accumulation while R. dentocariosa may drive community structure
in health. The shift along axis 1 comparing day 0 to 14 in teeth was negatively correlated
with R. dentocariosa (r=-0.86, p<0.01), indicating that R. dentocariosa may drive
community structure in health. The shift along axis 1 comparing day 0 to 21 in teeth was
positively correlated to F. nucleatum ss. animalis (r=0.78, p<0.01) and negatively
correlated with R. dentocariosa (r=-0.89, p<0.01), suggesting F. nucleatum ss. animalis
as the main driver of the shift in community structure after three weeks of plaque
accumulation while, again, R. dentocariosa drives community structure during health.
OTUs exhibiting a significant correlation with axis 1 in teeth prior to adjusting for
multiple comparisons are displayed in Tables 8-13. These also point to expected trends,
with species from the genera Prevotella, Fusobacterium, Selenomonas, Mogibacterium,
Atopobium, Treponema, among others, positively correlating with the shift during plaque
accumulation, while species from the genera Actinomyces, Streptococcus, Rothia and
some beta-Proteobacteria exhibited a negative correlation. In contrast to the changes
observed in community structure in teeth, which were expected and in accordance to
previous studies [18,22], there was not a consistent shift in community structure over
time for implants (Figures 15-17), suggesting that the microbiome response during
experimental plaque accumulation differs in teeth and implants, with an unpredictable
variable response in the latter. The Theta YC Index, which measures the distance
between samples from one time point to another and thus differences in community
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structure over time, for teeth and implants is displayed in Figure 18. This figure shows
that the magnitude of the shift during the experimental period was the same for teeth and
implants but implants did not shift in a predictable and consistent direction.

Figure 12. PCoA plot of community structure (Theta YC) in teeth from day 0 to day 7.
Gray = day 0; black = day 7. Red arrows indicate OTUs whose relative abundance was
significantly correlated with axis 1 and therefore drive variability along this axis.
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Figure 13. PCoA plot of community structure (Theta YC) in teeth from day 0 to day 14.
Gray = day 0; black = day 14. Red arrow indicates an OTU whose relative abundance
was significantly correlated with axis 1, driving variability along this axis.
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Figure 14. PCoA plot of community structure (Theta YC) in teeth from day 0 to day 21.
Gray = day 0; black = day 21. Red arrows indicate OTUs whose relative abundance was
significantly correlated with axis 1 and therefore drive variability along this axis.

Figure 15. PCoA plot of community structure (Theta YC) in implants from day 0 to day
7. Gray = day 0; black = day 7.
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Figure 16. PCoA plot of community structure (Theta YC) in implants from day 0 to day
14. Gray = day 0; black = day 14.

Figure 17. PCoA plot of community structure (Theta YC) in implants from day 0 to day
21. Gray = day 0; black = day 21.
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Table 8. Positive Spearman’s Rank-Order Correlations between OTUs and axis 1 for
teeth from day 0 to day 7 prior to adjusting for multiple comparisons. * = p<0.05; ** =
p<0.01
OTU
Veillonella parvula
Actinomyces sp. (HOT170)
Fusobacterium sp. (Fusobacterium nucleatum ss. animalis HOT420)
Prevotella salivae
Streptococcus sp. (HOT057)
Atopobium rimae
Actinomyces sp. HOT448
Fusobacterium sp. (Fusobacterium nucleatum ss. nucleatum HOT698)
Leptotrichia sp. HOT223
Oribacterium sp. (HOT372)
Selenomonas noxia
Mogibacterium sp. (Mogibacterium diversum HOT593)
Prevotella sp. HOT317
Prevotella oris
Neisseria bacilliformis HOT013
Lachnoanaerobaculum sp. (Eubacterium [XIVa][G-1] saburreum HOT494)
Prevotella denticola
Dialister invisus
Prevotella sp. HOT305

r
0.76**
0.69**
0.57**
0.53**
0.51**
0.47*
0.47*
0.47*
0.46*
0.43*
0.43*
0.43*
0.42*
0.42*
0.41*
0.40*
0.39*
0.38*
0.38*
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Table 9. Negative Spearman’s Rank-Order Correlations between OTUs and axis 1 for
teeth from day 0 to day 7 prior to adjusting for multiple comparisons. * = p<0.05; ** =
p<0.01
OTU
r
Rothia dentocariosa
-0.78**
Pseudomonas stutzeri
-0.49**
Acinetobacter baumannii
-0.44*
Delftia acidovorans HOT023 -0.41*
Halomonas sp.
-0.39*
Pseudoalteromonas sp.
-0.32*
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Table 10. Positive Spearman’s Rank-Order Correlations between OTUs and axis 1 for
teeth from day 0 to day 14 prior to adjusting for multiple comparisons. * = p<0.05; ** =
p<0.01
OTU
Veillonella parvula
Prevotella nigrescens
Campylobacter gracilis
Mogibacterium sp. (Mogibacterium diversum HOT593)
Fusobacterium sp. (Fusobacterium nucleatum ss. animalis)
Pseudoramibacter alactolyticus
Anaeroglobus geminatus
Solobacterium moorei
Veillonellaceae [G-1] HOT129
Anaeroglobus geminatus
Atopobium rimae
Neisseria oralis
Oribacterium sp. HOT102
Anaeroglobus geminatus
Atopobium rimae
Shuttleworthia satelles
Parvimonas micra
Prevotella multisaccharivorax
Comamonas testosteroni
Aggregatibacter actinomycetemcomitans
Alloprevotella rava
Aggregatibacter paraphrophilus
Parvimonas micra
Leptotrichia goodfellowii
Veillonella parvula
Fusobacterium sp. (Fusobacterium nucleatum ss. nucleatum)
Dialister invisus
Prevotella denticola
Prevotella oris

r
0.59**
0.58**
0.58**
0.57**
0.52**
0.50*
0.49*
0.48*
0.48*
0.47*
0.47*
0.46*
0.46*
0.46*
0.46*
0.46*
0.46*
0.46*
0.46*
0.46*
0.46*
0.43*
0.41*
0.40*
0.40*
0.40*
0.40*
0.39*
0.38*
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Table 11. Negative Spearman’s Rank-Order Correlations between OTUs and axis 1 for
teeth from day 0 to day 14 prior to adjusting for multiple comparisons. * = p<0.05; ** =
p<0.01
OTU
r
Rothia dentocariosa
-0.86**
Actinomyces sp. (HOT169)
-0.52**
Actinomyces sp. HOT171
-0.48*
Pseudomonas stutzeri
-0.45*
Actinomyces sp. HOT169
-0.44*
Acinetobacter baumannii
-0.42*
Streptococcus sp. (HOT068)
-0.42*
Leptotrichia sp. HOT221
-0.41*
Kingella oralis
-0.40*
Actinomyces sp. (Actinomyces naeslundii HOT176) -0.39*
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Table 12. Positive Spearman’s Rank-Order Correlations between OTUs and axis 1 for
teeth from day 0 to day 21 prior to adjusting for multiple comparisons. * = p<0.05; ** =
p<0.01
OTU
Fusobacterium nucleatum ss. animalis
Mogibacterium sp. (Mogibacterium diversum)
Prevotella oris
Prevotella nigrescens
Prevotella sp. (HOT292)
Selenomonas sp. (Selenomonas flueggei)
Fusobacterium sp. (Fusobacterium nucleatum ss. nucleatum)
Atopobium rimae
Selenomonas sp. HOT126
SR1 [G-1] sp. HOT874
Dialister invisus
Granulicatella elegans
Porphyromonas sp.
Treponema sp. (Treponema socranskii ss.paredis)
Oribacterium sp. (HOT372)
Atopobium rimae
Prevotella sp. HOT309
Eubacterium [XI][G-3] brachy
Campylobacter gracilis
Treponema sp. HOT237
Alloprevotella tannerae
Mitsuokella sp. HOT131
Prevotella denticola
Leptotrichia sp. (HOT392)
Porphyromonas sp. HOT279
Prevotella oris
Aggregatibacter sp. HOT512
Dialister pneumosintes
Selenomonas sputigena
Leptotrichia sp. HOT215
Solobacterium moorei
Treponema sp. (Treponema socranskii ss.socranskii)
Peptococcus sp. (HOT167)
Selenomonas sp. (HOT892)
Alloprevotella rava
Streptococcus mitis bv 2
Prevotella oulorum

r
0.78**
0.65**
0.65**
0.63**
0.56**
0.56**
0.53**
0.52**
0.51**
0.50**
0.49*
0.48*
0.48*
0.46*
0.46*
0.46*
0.45*
0.44*
0.44*
0.43*
0.43*
0.43*
0.42*
0.42*
0.42*
0.42*
0.42*
0.42*
0.41*
0.41*
0.41*
0.41*
0.40*
0.39*
0.39*
0.38*
0.38*
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Table 13. Negative Spearman’s Rank-Order Correlations between OTUs and axis 1 for
teeth from day 0 to day 21 prior to adjusting for multiple comparisons. * = p<0.05; ** =
p<0.01
OTU
r
Rothia dentocariosa
-0.89**
Actinomyces sp. (HOT169)
-0.57**
Actinomyces sp. (Actinomyces naeslundii HOT176) -0.50**
Acinetobacter baumannii
-0.49*
Pseudomonas stutzeri
-0.48*
unclassified Proteobacteria
-0.47*
Streptococcus sp. (HOT068)
-0.45*
Rothia mucilaginosa HOT681
-0.41*
Pseudoalteromonas sp.
-0.39*

Figure 18. Theta Index for teeth and implants over time. Bars indicate median and range.
No significant differences were found between groups.

OTUs that exhibited a significant difference in change in relative abundance from day 0
to day 21 prior to adjusting for multiple comparisons are displayed in Table 14 for teeth
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and Table 15 for implants. Several of the OTUs that demonstrated significant differences
in change in relative abundance from day 0 to day 21 were the same between implants
and teeth, including unclassified Proteobacteria, Pseudoalteromonas sp., Selenomonas sp.
(S. flueggei), unclassified Bradyrhizobiaceae (Afipia broomeae), Vibrio sp., Aeromonas
sp., Stenotrophomonas maltophilia, Pseudomonas sp. (P. pseudoalcaligenes), Prevotella
oris and Capnocytophaga leadbetteri. However, after adjusting for multiple comparisons,
there were no significant differences in relative abundance of any of the OTUs from day
0 to day 21 for teeth or implants.
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Table 14. OTUs that demonstrated significant differences in relative abundance from day
0 to day 21 in teeth prior to adjusting for multiple comparisons. * = p<0.05; ** = p<0.01
OTU
Fusobacterium sp. (F. nucleatum ss. polymorphum)
Alloprevotella tannerae
Prevotella oris
Prevotella oulorum
Aggregatibacter sp. (HOT458)
Selenomonas sputigena
Leptotrichia wadei
Porphyromonas sp. (P. catoniae)
Prevotella sp. (HOT292)
Selenomonas sp. (S. flueggei)
Streptococcus sp. HOT071
Atopobium parvulum
Moryella sp. (Moryella sp. HOT419)
Prevotella salivae
Oribacterium sp. (HOT372)
Prevotella maculosa
Megasphaera micronuciformis
Gemella morbillorum
Capnocytophaga leadbetteri
Selenomonas artemidis
Oribacterium sinus
Alloprevotella rava
Porphyromonas sp. (HOT275)
Lachnoanaerobaculum umeaense
Bacillaceae 1 sp.
unclassified Bradyrhizobiaceae (Afipia broomeae)
Stenotrophomonas maltophilia
Aeromonas sp.
Corynebacterium durum
Pseudomonas sp. (P. pseudoalcaligenes)
Pseudoalteromonas sp.
Vibrio sp.
Streptococcus sp. (HOT064)
unclassified Proteobacteria
Rothia dentocariosa

Δ Relative abundance day 0 to 21
0.0392*
0.0368*
0.0247*
0.0188*
0.0144*
0.0085*
0.0085*
0.0066*
0.0064*
0.0050*
0.0037*
0.0028*
0.0027*
0.0018*
0.0017*
0.0017*
0.0015*
0.0015*
0.0008*
0.0006*
0.0006*
0.0005*
0.0003*
0.0003*
-0.0001*
-0.0006*
-0.0006*
-0.0007*
-0.0008*
-0.0014*
-0.0021**
-0.0024*
-0.0052*
-0.0061**
-0.2432**
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Table 15. OTUs that demonstrated significant differences in relative abundance from day
0 to day 21 in implants prior to adjusting for multiple comparisons. * = p<0.05; ** =
p<0.01
OTU
Prevotella oris
Tannerella forsythia
Selenomonas sp. (S. flueggei)
Capnocytophaga leadbetteri
Eikenella corrodens
Treponema sp. (T. socranskii ss. socranskii)
Actinomyces sp. HOT181
Streptococcus sp. (HOT068)
Streptococcus sp. (S. australis)
Delftia acidovorans
Agrobacterium tumefaciens
Pseudomonas stutzeri
Gemella sanguinis
Actinomyces sp. (A. oris)
Streptococcus sp. (Streptococcus infantis)
Aeromonas sp.
unclassified Bradyrhizobiaceae (Afipia broomeae)
Actinomyces sp. (HOT170)
Streptococcus sp. (HOT055)
Rothia mucilagniosa
Stenotrophomonas maltophilia
Kingella oralis
Pseudomonas sp. (P. pseudoalcaligenes)
Pseudoalteromonas sp.
Granulicatella sp. (G.adiacens)
Vibrio sp.
unclassified Proteobacteria
Pasteurellaceae sp. (Terrahaemophilus aromaticivorans)

Δ Relative abundance day 0 to 21
0.0251*
0.0065*
0.0039*
0.0034*
0.0026*
0.0004*
-0.0003*
-0.0003*
-0.0003*
-0.0004*
-0.0004*
-0.0005*
-0.0006*
-0.0007*
-0.0015*
-0.0018*
-0.0021*
-0.0028*
-0.0037*
-0.0044*
-0.0044*
-0.0048*
-0.0061*
-0.0067*
-0.0071*
-0.0099*
-0.0276**
-0.1169*

To evaluate whether the change in OTU relative abundance occurred in the same manner
in teeth and implants, we compared via paired-sample Wilcoxon Signed-Rank tests the
changes (deltas) in relative abundance for all OTUs during the experimental phase. OTUs
that exhibited a significant difference in change in relative abundance between implants
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and teeth prior to adjusting for multiple comparisons are displayed in Figure 19 for day 0
to day 7, Figure 20 for day 0 to day 14 and Figure 21 for day 0 to day 21. In several
instances, the change in relative abundance of a particular OTU was positive for teeth but
negative for implants and vice versa (e.g., Corynebacterium durum from day 0 to day 7),
which is in accordance with the inconsistent response to plaque accumulation in implants
demonstrated in the PCoA plots. By day 21, several OTUs exhibited this behavior, with
some of the most striking differences being those of Streptococcus mitis bv 2 and
Streptococcus sp. HOT 071, and the periodontitis-associated OTUs Treponema
lecythinolyticum, Porphyromonas endodontalis, Tannerella forsythia and Bacteroidales
sp. HOT 272, which decreased in teeth during experimental plaque accumulation but
increased in implants. However, after adjusting for multiple comparisons, there were no
significant differences in the deltas (day 7-day 0; day 14-day 0; day 21-day 0),
representing change in relative abundance, of any of the OTUs between implants and
teeth.
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Figure 19. Change in relative abundance of OTUs that were statistically significantly
different between teeth and implants from day 0 to day 7 prior to adjusting for multiple
comparisons. Bars represent mean and standard deviation.
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Figure 20. Change in relative abundance of OTUs that were statistically significantly
different between teeth and implants from day 0 to day 14 prior to adjusting for multiple
comparisons. Bars represent mean and standard deviation.
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Figure 21. Change in relative abundance of OTUs that were statistically significantly
different between teeth and implants from day 0 to day 21 prior to adjusting for multiple
comparisons. Bars represent mean and standard deviation.
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In summary, there was higher plaque accumulation as evidenced by higher subgingival
bacterial load in teeth than implants. Diversity increased moderately during experimental
plaque accumulation in teeth only. A shift in community structure consistent with
previous studies was observed in teeth. In contrast, implants did not demonstrate an
increase in diversity and the direction of the shift in microbiome community structure
surrounding implants was inconsistent among subjects.

4.3 Results related to Aim 3
The third aim of this thesis (Aim 3) was to compare the immunological and
microbiological responses after oral hygiene measures are resumed around dental
implants and teeth.

4.4.1 Clinical results
Resumed oral hygiene resulted in a significant reduction in PlI from day 21 to day 42 for
both teeth and implants (Figure 4c) and this corresponded to a statistically significant
decrease in clinical inflammation, as measured by GI, in both teeth and implants (Figure
4b). GCF volume (Figure 4a) and ABS (Figure 4d) decreased significantly from day 21
to 42 in teeth but not in implants. However, there were no significant differences between
day -14 and day 42 for any of the clinical parameters for both implants and teeth,
indicating that implants and teeth return to their native state after three weeks of resumed
oral hygiene. On day 42, ABS was significantly higher at implants than teeth, suggesting
that clinical inflammation does not decrease as quickly at implants compared to teeth
once oral hygiene is reinstated (Figure 4d).
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4.4.2 GCF inflammatory marker results
IL-1 alpha (Figure 6a), IL-1 beta (Figure 6b) and IL-1 ra (Figure 6b) concentration
decreased significantly from day 21 to day 42 for both teeth and implants. Lactoferrin
concentration decreased significantly from day 21 to day 42 in teeth only (Figure 5a)
while CCL22 concentration decreased significantly from day 21 to day 42 in implants
only (Figure 5d). These results are consistent with the observations for these mediators as
markers of gingivitis, peri-implant mucositis or both during the experimental phase. IL-1
alpha, IL-1 beta and IL-1 ra seem to be consistent markers for experimental gingivitis and
peri-implant mucositis progression and resolution. Lactoferrin seems a marker for
experimental gingivitis progression and resolution only, whereas CCL22 marks
experimental peri-implant mucositis progression and resolution only. With the exception
of lactoferrin concentration at teeth (Figure 5a), there were no significant differences
between day -14 and day 42 for the inflammatory markers for both implants and teeth,
again indicating that implants and teeth return to their native state after three weeks of
resumed oral hygiene. Moreover, consistent with what was seen at the native state, on
day 42, implants tended to have greater levels of all inflammatory markers,
demonstrating statistically significantly higher concentrations of CCL22 (Figure 5d) and
TNF-alpha (Figure 6d) compared to teeth.

4.4.3 Microbiological results
Subgingival bacterial load was significantly lower on day 42 than day 21 for both teeth
and implants (Figure 8). Alpha diversity (Figure 9) was significantly lower on day 42
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than day 21 for teeth only. Intergroup comparisons showed no differences in subgingival
bacterial load and alpha diversity between teeth and implants at day 42. To evaluate
whether the change in OTU relative abundance occurred in the same manner in teeth and
implants, we compared the changes in relative abundance for all OTUs during resolution.
OTUs that demonstrated a significant difference in change in relative abundance between
implants and teeth prior to adjusting for multiple comparisons are displayed in Figure 22.
The change in relative abundance of R. dentocariosa was greater in teeth than implants.
The change in relative abundances of Streptococcus sp. HOT071 and Streprococcus sp.
(S. sanguinis), OTUs associated with health, increased in implants but decreased in teeth.
After adjusting for multiple comparisons, there were no significant differences in the
deltas (day 42-day 21), representing change in relative abundance, of any of the OTUs
between implants and teeth from day 21 to day 42.
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Figure 22. Change in relative abundance of OTUs that were statistically significantly
different between teeth and implants from day 21 to day 42 prior to adjusting for multiple
comparisons.

In summary, both teeth and implants returned to their native state as measured by clinical
parameters and host inflammatory and microbiological markers. Across group
comparisons showed that despite a lack of significant difference in PlI (Figure 4c), total
microbial load (Figure 8) or alpha diversity (Figure 9) between teeth and implants,
implants had more clinical inflammation, as measured by ABS, and higher concentrations
of some inflammatory markers than teeth during the resolution phase. This is similar to
the pre-experimental and experimental phase results.

4.5 Correlations in clinical, host and microbiological markers between teeth and
implants
Spearman’s Rank-Order correlations were calculated to determine whether clinical,
inflammatory and microbiological markers in implants and teeth were correlated at each
time point as well as at all time points taken together (Table 16). A positive correlation
indicates that the marker behaved in a subject-dependent manner in implants and teeth,
while negative correlation indicates that the marker behaved differently in implants
compared to teeth.
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Table 16. Spearman’s Rank-Order Correlations between test (implants) and control
(teeth) for each marker at each time point. Significant differences between groups are
indicated in bold.
Marker
GCF
GI
PlI
ABS
LF
MPO
IL-8
CCL-22
IL-1 alpha
IL-1 beta
IL-1 ra
TNF-alpha
GRO
Bacterial
Load
Richness
Evenness
Shannon
Index
Inverse
Simpson
Index

-14
0
7
0.01
-0.26
0.07
(NS)
(NS)
(NS)
0.64
0.37
(p<0.01)
(NS)
0.48
0.71
(NS)
(p<0.01)
0.51
0.17
0.34
(p<0.05)
(NS)
(NS)
0.39
0.01
-0.12
(NS)
(NS)
(NS)
0.18
0.14
0.00
(NS)
(NS)
(NS)
0.71
0.70
0.49
(p<0.01) (p<0.01)
(NS)
0.19
0.00
0.10
(NS)
(NS)
(NS)
-0.13
0.23
0.10
(NS)
(NS)
(NS)
0.13
0.06
0.25
(NS)
(NS)
(NS)
0.08
0.12
0.15
(NS)
(NS)
(NS)
0.32
0.55
0.35
(NS)
(p<0.05)
(NS)
-0.31
0.30
0.44
(NS)
(NS)
(NS)
-0.01
0.23
0.65
(NS)
(NS)
(p<0.01)
0.14
-0.39
0.53
(NS)
(NS)
(NS)
0.43
-0.07
0.24
(NS)
(NS)
(NS)
0.27
-0.09
0.34
(NS)
(NS)
(NS)
0.29
-0.04
0.43
(NS)
(NS)
(NS)

14
0.08
(NS)
0.40
(NS)
0.54
(p<0.05)
0.17
(NS)
0.54
(p<0.05)
0.37
(NS)
0.56
(p<0.05)
0.24
(NS)
0.23
(NS)
0.68
(p<0.01)
-0.18
(NS)
0.41
(NS)
0.60
(p<0.05)
0.24
(NS)
0.36
(NS)
0.12
(NS)
0.23
(NS)
0.19
(NS)

21
42
All
0.05
-0.06
0.14
(NS)
(NS)
(NS)
0.48
0.15
0.74
(NS)
(NS)
(p<0.01)
0.41
0.38
0.86
(NS)
(NS)
(p<0.01)
0.47
0.37
0.41
(NS)
(NS)
(p<0.01)
0.25
0.29
0.20
(NS)
(NS)
(NS)
0.06
0.48
0.26
(NS)
(NS)
(p<0.05)
0.53
0.89
0.68
(p<0.05) (p<0.01) (p<0.01)
-0.02
0.60
0.23
(NS)
(p<0.05) (p<0.05)
0.16
0.00
0.28
(NS)
(NS)
(p<0.01)
0.39
0.27
0.37
(NS)
(NS)
(p<0.01)
0.01
-0.16
0.23
(NS)
(NS)
(p<0.05)
0.75
0.18
0.46
(p<0.01)
(NS)
(p<0.01)
0.40
0.50
0.45
(NS)
(NS)
(p<0.01)
0.81
-0.01
0.46
(p<0.01)
(NS)
(p<0.01)
0.41
-0.03
0.14
(NS)
(NS)
(NS)
0.37
-0.06
0.14
(NS)
(NS)
(NS)
0.55
0.00
0.14
(p<0.05)
(NS)
(NS)
0.36
0.13
0.15
(NS)
(NS)
(NS)

71

4.5.1 Native condition
On day -14, there were several statistically significant between-group correlations. GI
(r=0.64, p<0.01) and ABS (r=0.51, p<0.05) and IL-8 (r=0.71, p<0.01) concentrations at
implants and teeth were correlated, which suggests that implants and teeth have similar
clinical inflammatory and PMN chemokine responses during the native condition (Table
16). There was also a trend for a positive correlation between PlI at implants and PlI at
teeth, suggesting that plaque accumulation in the native condition occurs in a subjectspecific manner. Interestingly, GCF volume and several inflammatory markers did not
show a significant correlation, a result in accordance with differences observed between
teeth and implants at day -14 (Figures 4-7), with implants showing a trend for higher
levels than teeth.

4.5.2 Experimental phase
There were several statistically significant between-group correlations during the
experimental phase (Table 16). On day 0, IL-8 (r=0.70, p<0.01), TNF-alpha (r=0.55,
p<0.05) and bacterial load (r=0.55, p<0.05) in teeth and implants were significantly
positively correlated. There were also significant positive correlations in teeth and
implants for bacterial load on day 7 (r=0.65, p<0.01) and day 21 (r=0.81, p<0.01),
suggesting that total 16S rRNA copy number varies in a subject-dependent manner in
implants and teeth during experimental gingivitis/peri-implant mucositis. Consistent with
this finding, PlI at teeth and implants was positively correlated on day 7 (r=0.71, p<0.01)
and also on day 14 (r=0.54, p<0.05). In addition to day 0, IL-8 at teeth was positively
correlated to IL-8 at implants on day 14 (r=0.56, p<0.05) and day 21 (r=0.53, p<0.05),
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although IL-8 concentration does not vary greatly during the experimental phase for teeth
or implants (Figure 5c). Lactoferrin (r=0.54, p<0.05), IL-1 beta (r=0.68, p<0.01) and
GRO (r=0.60, p<0.05) in teeth and implants were significantly positively correlated on
day 14. TNF-alpha (r=0.75, p<0.01) and non-parametric Shannon Index (r=0.55, p<0.05)
in teeth and implants were significantly positively correlated on day 14. Since several
clinical, inflammatory and microbiological markers in teeth and implants are positively
correlated to each other during the experimental phase, it seems that teeth and implants
respond in a subject-specific manner to plaque accumulation.

4.5.3 Resolution
On day 42, IL-8 (r=0.89, p<0.01) and CCL22 (r=0.60, p<0.05) concentrations at implants
and teeth were correlated, which suggests that these cytokines respond in a subjectspecific manner in implants and teeth during resolution (Table 16).

4.5.4 Correlations between teeth and implants at all visits
In order to evaluate if variation of biomarkers in teeth and implants was correlated across
the trial in a subject-dependent manner, we tested intergroup correlations taking into
account all time points. This analysis showed that regardless of time point, GI (r=0.74,
p<0.01), PlI (r=0.86, p<0.01) and ABS (r=0.41, p<0.01), but not GCF, were correlated
between implants and teeth (Table 16). These results suggest that the changes in these
parameters during the trial follow a subject-specific pattern despite differences in total
plaque accumulated by teeth and implants during the experimental phase (Figure 4).
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With the exception of lactoferrin, the host inflammatory marker concentrations in teeth
were correlated to those in implants overall (Table 16). This result may be due to the fact
that, as seen in figure 5a, lactoferrin concentration increased significantly as plaque
accumulation increased in teeth but it did not increase in implants.

Total 16S rRNA copy number in teeth was correlated to that in implants (r=0.46, p<0.01)
while alpha diversity in teeth was not correlated to that in implants overall (Table 14).
Subgingival bacterial load increased similarly in teeth and implants with increased plaque
(Figure 8). On the other hand, alpha diversity increased as plaque accumulation increased
in teeth but not in implants (Figure 9).

4.6 Correlations among all variables evaluated
In order to test which variables (clinical, host and microbiological) better correlated with
inflammation as determined by GI and ABS and with plaque accumulation as determined
by PlI and bacterial load, we determined Spearman’s Rank-Order correlations taking all
six visits together. All clinical and host marker variables were considered for this
analyses while selected OTUs were tested. OTUs selected for correlations in the teeth
group were those displaying the highest correlation coefficients with PC1 in PCoA
analysis plots during experimental plaque accumulation for the three time points tested.
OTUs selected for correlation analysis in the implant group were those displaying the
highest correlation coefficients with both PC1 and PC2 at day 21 only, as this was the
only day with more consistent trends in microbiome shifts in implants. The variables
were organized into correlograms based on results from hierarchical clustering for teeth
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(Figure 22) and implants (Figure 23). In teeth, GI was positively correlated with ABS, PlI,
subgingival bacterial load, MPO, lactoferrin, IL-1 alpha, IL-1 beta, IL-1 ra and the OTUs
C. gracilis, Selenomonas sp. (S. fluggei), Fusobacterium sp. (F. nucleatum ss. nucleatum)
and three OTUs in the genera Prevotella and negatively correlated with R. dentocariosa
(Figure 22). ABS in teeth was positively correlated with GI, PlI IL-1 alpha, IL-1 beta, IL1 ra, lactoferrin Fusobacterium sp. (F. nucleatum ss. animalis), Atopobium rimae and two
OTUs in the genera Prevotella (Figure 22). PlI in teeth in turn was positively correlated
with MPO, lactoferrin, IL-1 alpha, IL-1 beta, IL-1 ra, measures of alpha diversity, C.
gracilis, Selenomonas sp. (S. fluggei), Fusobacterium sp. (F. nucleatum ss. nucleatum)
and OTUs in the genera Prevotella and negatively correlated with R. dentocariosa
(Figure 22). Lastly, subgingival bacterial load in teeth was positively correlated with C.
gracilis, Selenomonas sp. (S. fluggei), OTUs in the genera Prevotella, IL-1 ra, IL-1 alpha
and TNF-alpha and negatively correlated with R. dentocariosa (Figure 22). Since IL-1
alpha, IL-1 beta, IL-1 ra (Figure 6a-c) and lactoferrin (Figure 5a) were biomarkers of
experimental plaque accumulation in teeth and Fusobacterium sp. (F. nucleatum ss.
animalis) was positively correlated with the shift in axis 1 from day 0 to day 21 in teeth
(Figure 14), these positive correlations were expected. Since R. dentocariosa was
negatively correlated with the shift in axis 1 from day 0 to day 7 (Figure 12), day 0 to day
14 (Figure 14) and day 0 to day 21 (Figure 14) in teeth, this negative correlation was
expected.

In implants, GI was positively correlated with MPO, lactoferrin, IL-1 alpha, IL-1 beta,
IL-1 ra and OTUs of the genera Treponema and Capnocytophaga sp. (C. gingivalis) and
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negatively correlated with R. dentocariosa and Streptococcus sp. (S. mitis; Figure 23).
ABS in implants was positively correlated with GRO, MPO, lactoferrin, IL-1 alpha, IL-1
beta and IL-1 ra alpha and negatively correlated with Streptococcus sp. (S. mitis; Figure
23). PlI in implants was positively correlated with IL-1 alpha, IL-1 beta, IL-1 ra and
Capnocytophaga sp. (C. gingivalis) and negatively correlated with R. dentocariosa.
Lastly, bacterial load in implant was positively correlated with TNF-alpha, CCL22 and
Eubacterium [XI][G-1]. Since IL-1 alpha, IL-1 beta, IL-1 ra (Figure 6a-c) and CCL22
(Figure 5d) were biomarkers of experimental plaque accumulation in implants, these
positive correlations were expected.
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Figure 22. Within group Spearman’s Rank-Order Correlations for teeth displayed as a
correlogram based on hierarchical clustering. Colors indicate correlation coefficients.
Non-significant correlations (more than 0.05) are marked with an x. Red = positive
correlation; purple = negative correlation. Samples were organized based on hierarchical
clustering results showing clusters of samples that correlate with each other.

Figure 23. Within group Spearman’s Rank-Order Correlations for implants displayed as
a correlogram based on hierarchical clustering. Colors indicate correlation coefficients.
Non-significant correlations (more than 0.05) are marked with an x. Red = positive
correlation; purple = negative correlation. Samples were organized based on hierarchical
clustering results showing clusters of samples that correlate with each other.
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We also employed Spearman’s Rank-Order Correlation test to examine whether presence
or absence of crowns on teeth was related to plaque accumulation since we observed
increased plaque accumulation in teeth in comparison to implants during the
experimental phase. A within group correlation analysis between presence of crowns and
PlI showed a significant negative correlation at day -14 and 42 and a trend toward a
negative correlation between the presence of a crown and increased PlI on day 7 and day
14, indicating that plaque accumulation tended to be lower in the presence of crowns
(Table 17).

Table 17. Spearman’s Rank-Order Correlations between presence of crowns and teeth PlI.
Day -14 and day 42 demonstrated significant negative correlations between presence of
crowns and PlI. Day 7 and 14 demonstrated a trend toward negative correlations between
presence of crowns and PlI.
Day -14

Day 7

Day 14

Day 21

Day 42

r

-0.58

-0.51

-0.45

-0.32

-0.77

p-value

0.02

0.05

0.09

0.23

.001

5. Discussion
This study aimed to compare clinical parameters, GCF inflammatory markers and
microbial biofilms between teeth and dental implants in their native state as well as to
evaluate the changes in clinical parameters, inflammatory markers and microbial biofilms
during 21 days of experimental plaque accumulation and after oral hygiene measures
were resumed around dental implants in comparison to teeth. The microbiome and host
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response associated with peri-implant mucositis is not fully understood. The prevention
and treatment of peri-implant mucositis is critical, as this condition may progress to periimplantitis and ultimately loss of the affected implant. Dissimilarities in the microbiomes
and/or host response associated with peri-implant mucositis versus gingivitis may guide
different clinical approaches to diagnosis, prevention and therapy. This is the first study
to characterize the evolution of the whole microbial profile and changes in host response
at teeth and implant sites during three phases: the native condition, experimental
gingivitis/peri-implant mucositis and resolution. Although this was a pilot study, subject
retention was high, with only three of 18 subjects lost. However, sample size was low and
the data were not normally distributed, which required the use of non-parametric
statistical tests, and adjustment for multiple comparisons was required as many variables
were compared. These factors rendered our tests conservative and may have hindered our
ability to discover true associations. Despite this, we observed several novel results and
also confirmed results of previous work. Our study may serve as a basis for larger
experiments of this nature.

During the native state (day -14), GI was significantly higher at teeth compared to
implants despite equal levels of plaque. In contrast, ABS and GCF volume tended to be
higher in implants than teeth during the native condition. Implants demonstrated
significantly higher concentrations of lactoferrin, IL-1 ra and TNF-alpha compared to
teeth. There was also a trend toward higher concentrations of MPO, CCL-22, IL-1 alpha,
IL-1 beta, IL-8 and GRO at implants compared to teeth. A trend for lower GI and a
statistically significant higher ABS in implants compared to teeth were also seen at the
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resolution phase (day 42). Also in agreement with day -14, higher levels of inflammatory
markers in implants and teeth were seen at the resolution phase. While all data point to
greater inflammation in implants in comparison to teeth, GI does not seem to correlate
well with molecular evidence of inflammation in implants. This may be due to
differences in histology of implants and teeth. For example, implants lack a PDL and
therefore the peri-implant mucosa has less vascularity than the gingiva. Since GI is a
visual assessment based on color, a decreased blood supply will result in less mucosal
color change. ABS, in contrast, seems to capture inflammation around implants.
Moreover, reasons for increased inflammation around implants in comparison to teeth
could not be explained by microbiome analysis, as implants did not have a unique or
different microbiome than that present on teeth. Subgingival bacterial load was also
similar between groups. These findings suggest the presence of a higher inflammatory
response in implants compared to natural teeth despite a similar microbial challenge. In
agreement with our results, Nowzari et al. (2012) reported significantly higher
concentrations of pro-inflammatory cytokines IL-8 and TNF-alpha in the peri-implant
sulcular fluid of healthy implants compared to the GCF of healthy teeth [11]. Differences
between teeth and dental implants in surface characteristics and chemical composition
may explain discrepancies in cytokine levels. When a foreign body, even commercially
pure titanium, is placed in bone or soft tissue, an inflammatory reaction develops.
Osseointegration of a dental implant is ultimately a foreign body response in the tissues.
The majority of implants experience a steady state foreign body reaction and maintain
osseointegration and healthy supporting tissues [61]. However, implants may
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demonstrate elevated local inflammatory cytokines compared to natural teeth due to this
foreign body response.

While PCoA revealed that community structure in teeth and implants is the same during
the native condition, there was a trend for differences in the relative abundances of a few
OTUs in teeth versus implants. There was a trend for the relative abundances of OTUs A.
gerencseriae and Capnocytophaga sp. (HOT336) to be greater in teeth compared to
implants whereas there was a trend for the relative abundances of P. melaninogenica and
P. salivae to be greater in implants compared to teeth. This is in agreement with Kumar et
al. (2012), who found higher levels of the genera Actinomyces and Capnocytophaga in
healthy teeth than healthy implants and higher levels of the genera Prevotella in healthy
implants than healthy teeth [37].

During the experimental phase, PlI increased significantly for both implants and teeth,
demonstrating that the methodology to induce plaque accumulation was effective.
However, teeth had higher PlI compared to implants over 21 days of oral hygiene
abstention. Increased plaque accumulation around unrestored teeth compared to ceramometal restorations as a result of differences in surface roughness has been previously
reported [62]. In our study, there was a trend toward a negative correlation between the
presence of crowns and PlI in teeth. Accordingly, implants demonstrated less plaque
accumulation than teeth. Consistent with higher PlI in teeth, GI tended to be higher in
teeth compared to implants, although this could be due to GI not being an accurate
marker of inflammation around implants. Salvi et al. (2012), on the other hand, found
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higher GI at implants compared to teeth despite higher PlI in teeth compared to implants
during experimental plaque accumulation [38]. Differences in methodology used to
measure GI between our study and the Salvi et al. (2012) study may explain the disparity
in these results. We measured GI using the Silness and Loe (1964) [42] method without
the bleeding component, according to the modification described by Trombelli et al.
(2004) [43]. Although this method was selected to allow plaque to accumulate in an
undisturbed manner throughout the experimental phase, the ability to distinguish between
a GI score of 1 and 2 is limited. This may have resulted in a less sensitive assessment of
GI. While the mGI method described by Mombelli et al. (1997) [63] used in the Salvi et
al. (2012) study may have allowed more accurate GI measurement, this technique
disturbed the biofilm weekly during experimental plaque accumulation. As explained
before, inflammation around implants may be better measured when there is a bleeding
component in the scale used, and therefore in this study ABS seemed to better reflect the
inflammatory status of implants than GI.

As plaque accumulation and clinical signs of inflammation increased over the
experimental phase, many of the inflammatory markers also increased. IL-1 alpha, IL-1
beta and IL-1 ra were the most consistent markers for plaque accumulation around both
teeth and implants. Lactoferrin was a marker of experimental gingivitis but not of periimplant mucositis while CCL22 was a marker for experimental peri-implant mucositis
only. Each of these mediators is characteristic of acute inflammation. IL-1 beta, produced
primarily by macrophages and PMNs, is a principal mediator of the gingival
inflammatory response and both IL-1 alpha and IL-1 beta stimulate PGE2 release.
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Elevated concentrations of IL-1 alpha and IL-1 beta have been associated with both
naturally occurring and experimental gingivitis [30-33]. In accordance with Salvi et al.
(2012)[38], IL-1 beta concentration increased as plaque accumulated in both implants and
teeth. While increased IL-1 ra concentration in periodontitis samples compared to healthy
samples has been reported, Il-1 ra has not been evaluated in gingivitis or peri-implant
mucositis. Consistent with previous periodontitis studies [34, 35], the concentration of
IL-1 ra increased in teeth during the experimental phase in our study. Implants also
demonstrated an increase in IL-1 ra during experimental peri-implant mucositis. Elevated
concentration of IL-1ra, the IL-1 receptor antagonist, during experimental plaque
accumulation may be explained by increased IL-1 ra secretion in response to IL-1 alpha
and IL-1 beta release in an attempt to dampen the inflammatory response. Since IL-1 ra
only binds the IL-1 beta receptor and does not affect IL-1 beta production, IL-1 beta
concentration increased despite increased IL-1 ra concentration during the experimental
phase. Binding of lipopolysaccharide (LPS) to Toll-like receptor 4 (TLR-4) is essential
for IL-1 alpha and IL-1 beta secretion in gingival tissue. Increased LPS, due to higher
proportions of gram-negative organisms as the plaque biofilm matures, stimulates
secretion of these cytokines [64]. Th17 cells, which require IL-1 for differentiation,
induce the production of osteoclastogenic mediators RANKL and TNF-alpha [65].
Therefore, IL-1 alpha and IL-1 beta, the central mediators in both experimental gingivitis
and peri-implant mucositis in our study, may be responsible for progression of
inflammation to an irreversible state (i.e., bone loss).
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The PMN marker lactoferrin was a biomarker for experimental gingivitis but not periimplant mucositis. The observation that lactoferrin concentration increased during
experimental plaque accumulation around teeth confirms the findings of Ozdemir et al.
(2009) [66]. Although higher concentrations of lactoferrin in the peri-implant sulcular
fluid of implants with peri-implantitis compared that of healthy implants have been
reported [12], lactoferrin was not a reliable marker of peri-implant mucositis in our study.
Perhaps lactoferrin is a better biomarker for more severe peri-implant lesions.

Produced by macrophages, CCL22 is a chemoattractant for Th2 cells and acted as a
biomarker for experimental peri-implant mucositis but not gingivitis. Recently, the
cytokine microenvironment in aseptic loosening of total hip replacements was described
in the orthopedic literature [67]. Compared to healthy synovial tissues of patients
undergoing primary hip replacement, interface tissues of failed hip implants
demonstrated upregulation of CCL22 and presence of foreign body giant cells. Similarly,
Albrektsson and colleagues introduced the theory that successful osseointegration of
dental implants relies on foreign body equilibrium [61,68]. This concept suggests that
marginal bone resorption around dental implants is ultimately the result of a provoked
foreign body response and is only secondarily related to biofilm-mediated processes.
Perhaps elevated CCL22 in implants, but not teeth, during experimental plaque
accumulation indicates a foreign body response to the titanium implant, exacerbated by
the bacterial biofilm. Finally, the fact that a macrophage-activity marker, but no
neutrophil marker, was significantly associated with peri-implant mucositis may indicate
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that inflammation in the peri-implant mucosa is more of a chronic than acute type
response.

Across group comparisons revealed significantly higher IL-1 ra, TNF-alpha and CCL22
concentrations at implants compared to teeth at various time points during the
experimental phase. These results are consistent with the trend for implants to display
higher levels of inflammatory markers than their teeth counterparts. Salvi et al. (2012)
also found higher MMP-8 concentration at implants compared to teeth during the
experimental phase, suggesting that implants develop a stronger inflammatory response
to experimental plaque accumulation than teeth [38].

The microbiological results from the experimental phase were largely consistent with
previous work from Löe et al. (1966)[18] and Kistler et al. (2013)[22] that demonstrated
a shift toward gram-negative, obligate anaerobes over the course of experimental
gingivitis. In our study, PCoA revealed a significant shift to the right along axis 1 as
plaque accumulated in teeth. This shift was positively correlated with V. parvula after
one week and F. nucleatum ss. animalis after three weeks and negatively correlated with
R. dentocariosa, indicating that V. parvula and F. nucleatum ss. animalis are drivers of
community structure during experimental plaque accumulation while R. dentocariosa
drives community structure in health. There was a trend for the relative abundances of
OTUs Selenomonas sp. (S. flueggei), S. sputigena, S. artemidis, Fusobacterium sp. (F.
nucleatum ss. polymorphum), Porphyromonas sp. (HOT275), Porphyromonas sp. (P.
catoniae) and L. wadei to increase from day 0 to day 21 in teeth. This is in agreement
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with Kistler et al. (2013), who found higher levels of the genera Selenomonas,
Fusobacterium, Porphyromonas and Leptotrichia during experimental gingivitis [22]. In
contrast to Kistler et al. (2013), who took plaque samples from the same sites each week,
we obtained biofilm samples from different sites throughout the study, allowing plaque to
accumulate in an undisturbed fashion. While this method was advantageous in that it
allowed the biofilm to mature over time, it also introduced variability, as the microbiome
could have been different at different sites.

This is the first study to characterize the whole microbiome during experimental periimplant mucositis. The magnitude of the shift in community structure over time, as
measured by Theta Index, was the same for teeth and implants. Moreover, the relative
abundances of many gram-negative OTUs, such as T. forsythia and Eikenella corrodens,
tended to increase, while gram-positive organisms, such as R. dentocariosa, tended to
decrease during experimental peri-implant mucositis, indicating a trend similar to teeth.
However, the shift in the microbiome structure was less predictable in implants compared
to teeth as evidenced by the different directions in which the microbiome community
structure shifted in PCoA analyses. Since the shift in community structure was consistent
in experimental gingivitis but inconsistent in experimental peri-implant mucositis, the
microbiome response during experimental plaque accumulation seems to differ between
teeth and implants. Perhaps surface characteristics determine different biofilm
development patterns in implants. It is also possible that since plaque did not accumulate
as much at implants, the peri-implant biofilm may not have had as much time to mature
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as the biofilm surrounding teeth, which may also explain why diversity increased from
day 0 to day 21 for teeth but not implants.

During resolution, all clinical parameters returned to their native state values for both
implants and teeth. However, ABS was significantly higher at implants than teeth on day
42, indicating that clinical inflammation does not decrease as quickly at implants
compared to teeth once oral hygiene practices are resumed. Salvi et al. (2012)[38] also
found greater clinical inflammation, as measured by GI, at implants compared to teeth on
day 42. Resolution of peri-implant mucositis may require a longer healing period than
gingivitis. Consistent with the experimental phase observations, IL-1 alpha, IL-1 beta and
IL-1 ra seem to be consistent markers for experimental gingivitis and peri-implant
mucositis resolution since the concentrations of these mediators decreased significantly
from day 21 to day 42 in both teeth and implants. Lactoferrin, which significantly from
day 21 to day 42 in teeth only, may act as a marker for experimental gingivitis resolution
only, whereas CCL22, which decreased significantly from day 21 to day 42 in implants
only, may act as a marker for experimental peri-implant mucositis resolution only.
Similar to the Salvi et al. (2012) host marker results, which demonstrated reversibility of
experimental gingivitis and peri-implant mucositis at the biomarker level [38], there were
no significant differences in inflammatory mediator concentration between the native
state and resolution for both implants and teeth. Although there were no differences in
subgingival bacterial load or diversity between implants and teeth on day 42, implants
tended to have greater levels of all inflammatory markers compared to teeth during
resolution. This observation is similar to the host marker findings during the native state.
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The within group correlations demonstrate that the host markers MPO, lactoferrin, IL-1
alpha, IL-1 beta and IL-1 ra best define gingivitis while IL-1 alpha, IL-1 beta, IL-1 ra,
CCL22 and TNF-alpha best define peri-implant mucositis. OTUs such as C. gracilis,
Selenomonas sp. (S. fluggei), Fusobacterium sp. (F. nucleatum ss. nucleatum) and
Fusobacterium sp. (F. nucleatum ss. animalis) and the genera Prevotella were correlated
with gingivitis. C. gracilis, Fusobacterium sp. (F. nucleatum ss. nucleatum) and
Fusobacterium sp. (F. nucleatum ss. animalis) have been previously defined as core
species present in at least 50% of subjects in both healthy and periodontitis groups [69].
In contrast, OTUs including Capnocytophaga sp. (C. gingivalis) and Eubacterium
[XI][G-1] and the genera Treponema were associated peri-implant mucositis.
Eubacterium [XI][G-1] and OTUs of the genera Treponema were identified as members
of the core microbiome in periodontitis [69], suggesting that the microbial profile
associated with peri-implant mucositis may have pathogenic consequences.
As expected, R. dentocariosa, a member of the core microbiome in periodontal health,
was negatively correlated with both gingivitis and peri-implant mucositis. Genera
correlated with gingivitis, such as Fusobacterium and Selenomonas, and peri-implant
mucositis, such as Eubacterium and Treponema, in our study predicted gingivitis in the
study by Huang et al. (2014)[23]. The key host markers for gingivitis and peri-implant
mucositis described above could be used to develop assays for the presence and severity
of inflammatory disease around teeth and implants. Similarly, tests related to
identification of organisms associated with gingivitis or peri-implant mucositis in this
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pilot study may be useful for clinical diagnosis. However, such cytokine and microbial
tests would require validation in larger cohort studies.

6. Conclusions
From the work reported herein, it can be concluded that:
•

In the native condition, dental implants have higher concentrations of host
inflammatory mediators than their teeth counterparts despite equal level of
bacterial plaque and similar microbiome structure.

•

IL-1 alpha, IL-1 beta and IL-ra are consistent biomarkers of both experimental
gingivitis and peri-implant mucositis, which suggests that both lesions may
advance in a similar manner. Lactoferrin, however, is a biomarker for
experimental gingivitis but not peri-implant mucositis while CCL22 is a
biomarker for experimental peri-implant mucositis but not gingivitis.

•

During experimental plaque accumulation, the structure of the microbiome
surrounding teeth evolves in a consistent and predictable direction. On the other
hand, the shift in microbiome community structure during experimental plaque
accumulation was less predictable for implants. Teeth accumulate more plaque
than implants and also demonstrate an increase in diversity of the biofilm as
plaque accumulates whereas implants do not show changes in diversity.

•

The main drivers of shifts in microbiome structure are V. parvula, Fusobacterium
sp. (F. nucleatum ss. animalis) and R. dentocariosa around teeth and R.
dentocariosa and OTUs of the genera Actinomyces around implants.
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•

After 21 days of oral hygiene reinstitution, the gingiva and peri-implant mucosa
return to their native clinical condition. However, implants have higher ABS
compared to teeth during resolution. Implants may require longer healing periods
than teeth after experimental plaque accumulation.

•

Similar to the native state, implants demonstrate higher levels of inflammatory
mediators than teeth during resolution.
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